"primary_key","object_id","product_family_id","product_family_name","product_family_number","laststreameddate","itemref","spec_id","version","product_or_material_description","version_status","spec_name","notes","common","local_ref","create_by","approved_by","approval_reason","smd_reference","make_current","analysis","measurement","concatenate_cqa","limit_type_id","limit_1","limit_2","units","stability"
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a4-871d-7204-abf0-d793e96991b4-123-Spec-00040113|24|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a4-871d-7204-abf0-d793e96991b4","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|24|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"24",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"15-Aug-2024 tlinack (SC) - Update of specification for commercial purpose as per ETS 2365185
1. Added Inhouse Reference to GLO + CHAR + IPC Limit Type
2. Added GLO 1, CHAR 1, IPC 1, ALERT and CLIN, CHAR 2, IPC 2 Limit Types
3. Added references on the INH Limit Type
4. Removed limits according to TV-SPEC-67180 v3.0 from the INH Limit Type
5. Updated WS on BIOBURDEN 1
6. Updated CoA Translation on IC COLOR INST SAMPLE (v2) 1NC 3TC 3T 3L, result EP-B rep + result EP-BY rep + result EP-Y rep
7. Updated Threshold as per provided Supplemental Info on SUCROSE (v1) 1N, but not on SE-HPLC (v1) 3N 1LIST 1, because this is not in alignment with site request
8. Updated unit on POLYSORBATE 80 (v1) 1N to ""% (w/v)""
NOTE: POLYSORBATE 80 (v1) 1N and SUCROSE (v1) 1N were set up with ""% (w/v)"" for all limit type per guidance of QC. This unit was chosen because this is the unit which is used in the COMM lab spec and in the TMDs. QC did't want to have an extra Parameter list with only ""%"" for CLIN and or PPQ purpose.
9. Updated CoA Translation and or CoA Group and or CoA Limit Text as per TV-SPEC-69985 v1.0 (GLO 1&CHAR 1) required, and added extended CoA Information as per TV-SPEC-67180 v3.0 (GLO&CHAR) and  TV-SPEC-66430 v5.0 (CLIN%CHAR2) as needed on following PL:
-POLYSORBATE 80 (v1) 1N
-PARTICULATE MATTER (v1) CNTO4424 1LIST
-PARTICULATE MATTER 7 (v1) 1LIST
-MDI 3RUN 10 25 70 C (v1) 2DATE 37N 15NC
-IC SUBVIS 11 (v1) 3N 8NC 5DATE 1T 1L
-IC A280 SAMPLE (v1) 6N 4NC
-PH20 ACTIVITY (v1) 1N
-CSDS REDUCED (v1) CNTO4424 2N 1LIST
-CSDS NON-REDUCED (v1) 1N 1LIST 2
-PEPTIDE MAPPING 1 (v1) 5N

NOTE:
PARTICULATE MATTER (v1) CNTO4424 1LIST + IC VFP STG1+ IC VFP STG2.1 + IC VFP STG3.1 is in use for 10mL 
PARTICULATE MATTER 7 (v1) 1LIST + IC VFP STG1 A+ IC VFP STG2.1 A + IC VFP STG3.1 A is in use for 14 mL and 15 mL
PARTICULATE MATTER 8 (v1) 1LIST + IC VFP STG1 B+ IC VFP STG2.1 B + IC VFP STG3.1 B is in use for 22mL",,,tlinack,lwerner3,ETS 2365185/  2365189,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Mon Sep 02 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a4-cfe0-79ce-9249-466091e37249-123-Spec-00024378|10|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276a4-cfe0-79ce-9249-466091e37249","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00024378|10|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00024378,"10",JNJ-61186372 (CNTO 4424) 50 mg/mL Formulated Bulk,A,Specification and Justification of Specifications for Clinical JNJ-61186372 (CNTO 4424) 50 mg/mL Formulated Bulk (Global MM# 309278),"TASK000017288742 amchugh2 01MAR19  > Updated SMD Version to 2.0  >Added POLYSORBATE (v1) 1 PCT, SUBUNIT LCMS (v1) 1TEXT, GLYCATION ANALYSIS (v1) 1TEXT & FREE THIOL (v1) 1TEXT  > Updated CIEF (v1) 9N 1LIST 4, CSDS REDUCED (v1) CNTO4424 2N 1LIST, HI HPLC (v1) 3N & SE-HPLC (v1) 3N  > Updated CoA Group & CoA Translation for OD280 C 1 (v1) 5N 3NC   > Update CoA Translation BIOASSAY 1 2N  ",,,amchugh2,loconno5,,"TV-SPEC-50156, DS-SPE-34672",Mon Apr 08 11:48:45 EDT 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a4-d5a5-719e-9cbf-0cfa2213e6ee-123-Spec-00040113|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a4-d5a5-719e-9cbf-0cfa2213e6ee","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"11",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"sshank28 (GVW) - 15/Mar/2024 - Schaffhausen - Update of specification report.
1. Updated Specification Name and Description.
2. Updated SMD Reference from TV-SPEC-67180 v1.0, TV-VAL-256281 v2.0 to TV-SPEC-67180 v2.0, TV-VAL-256281 v2.0 for Limit Type INH.
3. Updated SMD Reference from TV-SPEC-67180 v1.0 to TV-SPEC-67180 v2.0 for Limit Types GLO and CHAR.
4. Updated CoA Translation for parameter lists PARTICULATE MATTER and PARTICULATE MATTER 7.
5. Updated Method Reference for parameter lists BIOASSAY 15 and BIOASSAY.",,,sshank28,tlinack,TV-SPEC-67180 v2.0,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri Mar 22 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a4-d631-7d9a-8eb8-5b74e5888e02-123-Spec-00040113|19|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a4-d631-7d9a-8eb8-5b74e5888e02","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|19|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"19",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"MVarghee (GVW) - 01/Jul/2024 - CC 2358213 - Update of Specification report as per LCRF.
1. Updated Threshold Limit, Operator and Threshold Value 1 for parameter Component 1 of parameter list SE-HPLC. 
2. Updated Threshold Limits and Threshold Value 1 for parameter Component 2 and Component 3 of parameter list SE-HPLC.",,,MVarghee,lwerner3,update according to CC 2358213 and LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Mon Jul 08 10:28:11 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a4-d780-79e0-9284-3bccd653fb4c-123-Spec-00040098|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a4-d780-79e0-9284-3bccd653fb4c","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"14",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"19APR2024 RISU (GQS) Updated GLO and CHAR limits and method references and worklist for  BIOASSAY (v1) 2N per site LCRF. and adjusted references and limits for IC BIOASSAY SAC ST1 (v1) 1LIST 13N 1NC, IC BIOASSAY SAC ST2 (v1) 1LIST 11N 14NC accordingly to keep alignment TV-SPEC-67180 v2.0",,,RSuidgee,WVeen1,,TV-SPEC-67180,Fri Apr 19 11:30:14 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a5-7575-7f44-a7b5-cc51cd57f141-123-Spec-00026801|2|8N 14NC|DIL HIC REAGENTS : Component 15|INH|>=|10.0|||UL","019276a5-7575-7f44-a7b5-cc51cd57f141","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00026801|2|8N 14NC|DIL HIC REAGENTS : Component 15|INH|>=|10.0|||UL,Spec-00026801,"2",SPECIFICATION FOR LME: EL-LB-HICHPLC-CNTO4424,A,SPECIFICATION FOR LME: EL-LB-HICHPLC-CNTO4424,"16-Apr-2021 - nsubhakd(GVW) - CC#1545784- Update to the spec   1. Updated Spec name and description  2. Added Parameter List ID DIL HIC REAGENTS  -8N 14NC",,,nsubhakd,tshah1,Approved per CC#1545784.,,Mon Apr 19 17:25:00 EDT 2021,DIL HIC REAGENTS,Component 15,DIL HIC REAGENTS : Component 15,INH,>= 10.0,,uL,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a5-822a-7c55-8e3a-a752385b2906-123-Spec-00039784|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a5-822a-7c55-8e3a-a752385b2906","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"14",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"16Jul2024 Mcolli34 (eLIMS global) As per LCRF:
1) For Parameter IC ENDTOX SAMPLE 5N 4T 1NC component 1, updated CoA translation to ""Dilution factor = 50x in LRW"" , and added INH limit of =50
2) For parameter IC PH MEASUREMENT 2TEXT 3N component Sample Method ID (Standard), updated INH limit to 'PH MEASUR'
",,,Mcolli34,tshah1,Reviewed/Apporved.,TV-SPEC-67179,Tue Jul 16 12:59:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a5-f13f-7ad5-9c0e-b72c5531951b-123-Spec-00039784|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a5-f13f-7ad5-9c0e-b72c5531951b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"11",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"23Feb2024 Mcolli34 (eLIMS Global) As per LCRF:
1)Added INH limits for parameters IC CMET BIND SAC (v1) 7N 1NC and IC BIOASSAY SAC ST1 (v1) 1LIST 13N 1NC
2) Updated Technique for all parameters
",,,Mcolli34,tshah1,Reviewed/Approved.,TV-SPEC-67179,Tue Apr 23 15:31:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a6-aa61-7de4-8382-bea385386082-123-Spec-00040113|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a6-aa61-7de4-8382-bea385386082","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"13",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"MVarghee (GVW) - 17/Apr/2024 - Schaffhausen - Update of Specification report as per LCRF.
1. Added Parameter List SAMPLE DILUTION 1C.

sademosk (SC) - 19/Apr/2024 - Schaffhausen - 
2. Sequence adjusted, SAMPLE DILUTION 1C (v1) 2N 1NC moved under PEPTIDE MAPPING 1 (v1) 5N

",,,MVarghee,tlinack,LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Tue Apr 23 10:31:14 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a7-1298-794b-95c5-711d3cc3dc11-123-Spec-00040113|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a7-1298-794b-95c5-711d3cc3dc11","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"4",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE,"14-Jul-2023 - RKrish50(GVW) - ETS 1939431 - Update of Specification for the addition of Parameter  list ID IC COLOR INST SAMPLE - 1NC 3TC 3T 3L.

18-Jul-2023 tlinack (SC)
1. Updated Template of COLOR OF SOLUTION 1 (v1) 3LIST from EL-SC-COLOR INSTR-1 to EL-SC-COLOR-1 (Parameter list will be used only for back-up purpose and therefore not added to the SPL)
2. Update Limit on INH and GLO limit type for CIEF (v1) 3N 1LIST 6, Component 4",,,RKrish50,nshah32,,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jul 19 15:35:21 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a7-76e1-7553-8b0a-2ad4aa6dc3e2-123-Spec-00040113|22|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a7-76e1-7553-8b0a-2ad4aa6dc3e2","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|22|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"22",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"18-Jul-2024 tlinack (SC) - Created version in error, no updates were performed.

19-Jul-2024 tlinack (SC) - Spec-00040113 according to CoC 2162510 + LCRF
1. Template EL-SC-VFP-25 added to Param List PARTICULATE MATTER 8 (v1) 1LIST 
2. Template EL-SC-VFP-25 added to Param List IC VFP STG1 B (2D 2C 2L)
",,,tlinack,sademosk,CoC 2162510 ,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Tue Jul 23 10:51:34 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a7-b97f-7f2a-9aaf-9a954513fad6-123-Spec-00039784|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a7-b97f-7f2a-9aaf-9a954513fad6","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"15",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"PKuruva (GVW) - 24/Jul/2024 - Update of specification as per LCRF.
1. Removed Worksheet Template for BIOASSAY parameter list.
2. Updated Worksheet Template for DOT BLOT IDENTITY parameter list.
3. Added BINDING ASSAY 1 and BIOASSAY 1 parameter lists.
",,,pkuruva,Mcolli34,Reviewed/Approved as per LCRF,TV-SPEC-67179,Fri Jul 26 15:41:26 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a8-0c5c-731d-bdb4-f03009204cf8-123-Spec-00023860|9|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276a8-0c5c-731d-bdb4-f03009204cf8","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00023860|9|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00023860,"9","JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B",A,"JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B Acceptance Criteria","joconn40 Cork_API-L 09Dec19- Updated method reference for Turbidity and updated worklists for Bioassay 13, CSDS R, CSDS NR, SE-HPLC and CIEF.",,,joconn40,loconno5,,,Tue Dec 10 09:01:33 EST 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a8-5c52-7feb-b928-6390e3a40174-123-Spec-00024378|9|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276a8-5c52-7feb-b928-6390e3a40174","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00024378|9|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00024378,"9",JNJ-61186372 (CNTO 4424) 50 mg/mL Formulated Bulk,A,Specification and Justification of Specifications for Clinical JNJ-61186372 (CNTO 4424) 50 mg/mL Formulated Bulk (Global MM# 309278),"TASK000017288742 amchugh2 01MAR19  > Updated SMD Version to 2.0  >Added POLYSORBATE 80 (v1) 1TEXT, SUBUNIT LCMS (v1) 1TEXT, GLYCATION ANALYSIS (v1) 1TEXT & FREE THIOL (v1) 1TEXT  > Updated CIEF (v1) 9N 1LIST 4, CSDS REDUCED (v1) CNTO4424 2N 1LIST, HI HPLC (v1) 3N & SE-HPLC (v1) 3N  > Updated CoA Group & CoA Translation for OD280 C 1 (v1) 5N 3NC   > Update CoA Translation BIOASSAY 1 2N  ",,,amchugh2,loconno5,,"TV-SPEC-50156, DS-SPE-34672",Wed Mar 06 12:10:46 EST 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a9-29cb-746d-b899-9d2fd00ac5f5-123-Spec-00040098|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a9-29cb-746d-b899-9d2fd00ac5f5","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"2",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"28/Jul/2023 - pkalaimo (GVW) - Update of specification as per LCRF.
1. Added Worksheet Template for all applicable parameter lists.",,,pkalaimo,mari1,Reviewed and Approved,TV-SPEC-67180,Mon Jul 31 15:28:50 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a9-806f-7343-966d-0946fcf20971-123-Spec-00040098|17|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276a9-806f-7343-966d-0946fcf20971","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|17|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"17",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"12Jul2024 Mcolli34 (eLIMS Global) As per LCRF:
1) Removed parameter IC SUBVIS 11 3N 8NC 5DATE 1T 1L 
",,,Mcolli34,mari1,Reviewed and Approved,TV-SPEC-67180,Mon Jul 15 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276a9-84f2-74f2-acc0-5ebc842c2c9f-123-Spec-00040113|24|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","019276a9-84f2-74f2-acc0-5ebc842c2c9f","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|24|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"24",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"15-Aug-2024 tlinack (SC) - Update of specification for commercial purpose as per ETS 2365185
1. Added Inhouse Reference to GLO + CHAR + IPC Limit Type
2. Added GLO 1, CHAR 1, IPC 1, ALERT and CLIN, CHAR 2, IPC 2 Limit Types
3. Added references on the INH Limit Type
4. Removed limits according to TV-SPEC-67180 v3.0 from the INH Limit Type
5. Updated WS on BIOBURDEN 1
6. Updated CoA Translation on IC COLOR INST SAMPLE (v2) 1NC 3TC 3T 3L, result EP-B rep + result EP-BY rep + result EP-Y rep
7. Updated Threshold as per provided Supplemental Info on SUCROSE (v1) 1N, but not on SE-HPLC (v1) 3N 1LIST 1, because this is not in alignment with site request
8. Updated unit on POLYSORBATE 80 (v1) 1N to ""% (w/v)""
NOTE: POLYSORBATE 80 (v1) 1N and SUCROSE (v1) 1N were set up with ""% (w/v)"" for all limit type per guidance of QC. This unit was chosen because this is the unit which is used in the COMM lab spec and in the TMDs. QC did't want to have an extra Parameter list with only ""%"" for CLIN and or PPQ purpose.
9. Updated CoA Translation and or CoA Group and or CoA Limit Text as per TV-SPEC-69985 v1.0 (GLO 1&CHAR 1) required, and added extended CoA Information as per TV-SPEC-67180 v3.0 (GLO&CHAR) and  TV-SPEC-66430 v5.0 (CLIN%CHAR2) as needed on following PL:
-POLYSORBATE 80 (v1) 1N
-PARTICULATE MATTER (v1) CNTO4424 1LIST
-PARTICULATE MATTER 7 (v1) 1LIST
-MDI 3RUN 10 25 70 C (v1) 2DATE 37N 15NC
-IC SUBVIS 11 (v1) 3N 8NC 5DATE 1T 1L
-IC A280 SAMPLE (v1) 6N 4NC
-PH20 ACTIVITY (v1) 1N
-CSDS REDUCED (v1) CNTO4424 2N 1LIST
-CSDS NON-REDUCED (v1) 1N 1LIST 2
-PEPTIDE MAPPING 1 (v1) 5N

NOTE:
PARTICULATE MATTER (v1) CNTO4424 1LIST + IC VFP STG1+ IC VFP STG2.1 + IC VFP STG3.1 is in use for 10mL 
PARTICULATE MATTER 7 (v1) 1LIST + IC VFP STG1 A+ IC VFP STG2.1 A + IC VFP STG3.1 A is in use for 14 mL and 15 mL
PARTICULATE MATTER 8 (v1) 1LIST + IC VFP STG1 B+ IC VFP STG2.1 B + IC VFP STG3.1 B is in use for 22mL",,,tlinack,lwerner3,ETS 2365185/  2365189,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Mon Sep 02 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ab-6977-76a7-a504-38a826f03475-123-Spec-00039784|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ab-6977-76a7-a504-38a826f03475","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"8",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (GLOBAL MM# 310817),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (GLOBAL MM# 310817),"11/Sep/2023 - Mari1 (QCO) - Update of specification as per LCRF.
1. Removed ""PEPTIDE MAPPING 1 - 1N parameter lists and Added PEPTIDE MAPPING 15N test.
2. Removed GLYCATION 1 - 1TEXT parameter lists and Added GLYCATION 1N test.
3. Removed SUBUNIT MASS - 1TEXT parameter lists and Added SUBUNIT MASS - 2TEXT test.",,,mari1,tshah1,Reviewed and Approved.,TV-SPEC-67179,Tue Sep 12 12:54:00 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ac-18db-790b-963f-0325ffb9db89-123-Spec-00043112|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ac-18db-790b-963f-0325ffb9db89","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"1","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",pkalaimo (GVW) - 07/Aug/2024 - Upload of specification as per TruVault Document.,,,pkalaimo,nchadwi2,GQS Review/approval,TV-SPEC-69985,Tue Aug 27 09:13:52 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ac-6b98-7f96-9ff7-1e43c58b1891-123-Spec-00040098|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ac-6b98-7f96-9ff7-1e43c58b1891","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"8",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"30-Nov-2023 - amagflorGVW) - CC#2256900 - Updated the Specification for
- To replace the Parameter list ID BIOASSAY 1 -2N with IC CMET BIND SAC - 7N 1NC.
- To replace the Parameter List ID BIOASSAY 2-2N with IC BIOASSAY SAC ST1 - 1LIST 13N 1NC and IC BIOASSAY SAC ST2 - 1LIST 11N 14NC.",,,amagflor,CGallag9,Reviewed/Approved,TV-SPEC-67180,Mon Dec 04 01:00:00 EST 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ad-24d0-72d5-9598-7526104ec276-123-Spec-00040098|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ad-24d0-72d5-9598-7526104ec276","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"11",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"pkalaimo (GVW) - 05/Feb/2024 - LM - Update of specification as per LCRF.
1. Replaced CIEF - 7N 1LIST 4 with CIEF - 8N 1LIST parameter list.",,,pkalaimo,mari1,Reviewed and Approved,TV-SPEC-67180,Thu Feb 08 14:05:41 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ad-5d8a-728d-8134-81d09df139b4-123-Spec-00040098|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ad-5d8a-728d-8134-81d09df139b4","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"5",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"04/Oct/2023 - PSivaper (GVW) - Update of specification as per LCRF.
1. Updated INH Limit for parameter ""Sample Method ID"" of IC PH MEASUREMENT parameter list.

29/Sep/2023 - VKumara1 (GVW) - CC 2267208 - Update of specification as per LCRF.
1. Added CDS Name for parameters “Component 1” and “Component 2” of CSDS REDUCED parameter list.
2. Added CDS Name for parameter “Component 1” of CSDS NON-REDUCED parameter list.
3. Added CDS Name for NEW PEAKS and NEW PEAKS 1 parameter lists.
Skuijla2 06OCT2023: CSD Name updates Reviewed and Approved",,,VKumara1,mari1,Reviewed and Approved,TV-SPEC-67180,Fri Oct 06 14:07:55 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ad-d7eb-776c-ac77-d2fd510d8181-123-Spec-00040098|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ad-d7eb-776c-ac77-d2fd510d8181","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"7",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"16/Oct/2023 - sdanie24 (GVW) - Update of specification as per LCRF.
1. Updated Worksheet Template for BIOASSAY parameter list.",,,sdanie24,tshah1,Reviewed and Approved.,TV-SPEC-67180,Wed Oct 18 18:11:00 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ae-2ff2-7eb6-ac20-caa5c92ff5e4-123-Spec-00040113|21|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ae-2ff2-7eb6-ac20-caa5c92ff5e4","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|21|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"21",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"15-Jul-2024 tlinack (SC) - Update of Specification report as per LCRF (ETS 2330275).
1. Updated acceptance criteria on INT Limit for IC SUBVIS 11 (v1) 3N 8NC 5DATE 1T 1L on component ""Target Fill Volume"".",,,tlinack,lwerner3,update according to LCRF and (ETS 2330275),"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Mon Jul 15 09:44:05 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276af-a069-7e18-aeeb-62e8539bb7c7-123-Spec-00023860|6|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276af-a069-7e18-aeeb-62e8539bb7c7","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00023860|6|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00023860,"6","JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B",A,"JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B Acceptance Criteria",joconn40 Cork_API-L 11Jul19- Updated SMD reference and updated CoA translation for HI HPLC (v1) 3N,,,joconn40,loconno5,,,Thu Jul 11 12:49:49 EDT 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276af-df9b-782b-95c6-a97e81e52b09-123-Spec-00040113|24|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","019276af-df9b-782b-95c6-a97e81e52b09","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|24|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"24",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"15-Aug-2024 tlinack (SC) - Update of specification for commercial purpose as per ETS 2365185
1. Added Inhouse Reference to GLO + CHAR + IPC Limit Type
2. Added GLO 1, CHAR 1, IPC 1, ALERT and CLIN, CHAR 2, IPC 2 Limit Types
3. Added references on the INH Limit Type
4. Removed limits according to TV-SPEC-67180 v3.0 from the INH Limit Type
5. Updated WS on BIOBURDEN 1
6. Updated CoA Translation on IC COLOR INST SAMPLE (v2) 1NC 3TC 3T 3L, result EP-B rep + result EP-BY rep + result EP-Y rep
7. Updated Threshold as per provided Supplemental Info on SUCROSE (v1) 1N, but not on SE-HPLC (v1) 3N 1LIST 1, because this is not in alignment with site request
8. Updated unit on POLYSORBATE 80 (v1) 1N to ""% (w/v)""
NOTE: POLYSORBATE 80 (v1) 1N and SUCROSE (v1) 1N were set up with ""% (w/v)"" for all limit type per guidance of QC. This unit was chosen because this is the unit which is used in the COMM lab spec and in the TMDs. QC did't want to have an extra Parameter list with only ""%"" for CLIN and or PPQ purpose.
9. Updated CoA Translation and or CoA Group and or CoA Limit Text as per TV-SPEC-69985 v1.0 (GLO 1&CHAR 1) required, and added extended CoA Information as per TV-SPEC-67180 v3.0 (GLO&CHAR) and  TV-SPEC-66430 v5.0 (CLIN%CHAR2) as needed on following PL:
-POLYSORBATE 80 (v1) 1N
-PARTICULATE MATTER (v1) CNTO4424 1LIST
-PARTICULATE MATTER 7 (v1) 1LIST
-MDI 3RUN 10 25 70 C (v1) 2DATE 37N 15NC
-IC SUBVIS 11 (v1) 3N 8NC 5DATE 1T 1L
-IC A280 SAMPLE (v1) 6N 4NC
-PH20 ACTIVITY (v1) 1N
-CSDS REDUCED (v1) CNTO4424 2N 1LIST
-CSDS NON-REDUCED (v1) 1N 1LIST 2
-PEPTIDE MAPPING 1 (v1) 5N

NOTE:
PARTICULATE MATTER (v1) CNTO4424 1LIST + IC VFP STG1+ IC VFP STG2.1 + IC VFP STG3.1 is in use for 10mL 
PARTICULATE MATTER 7 (v1) 1LIST + IC VFP STG1 A+ IC VFP STG2.1 A + IC VFP STG3.1 A is in use for 14 mL and 15 mL
PARTICULATE MATTER 8 (v1) 1LIST + IC VFP STG1 B+ IC VFP STG2.1 B + IC VFP STG3.1 B is in use for 22mL",,,tlinack,lwerner3,ETS 2365185/  2365189,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Mon Sep 02 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b0-275d-76fd-b531-6149d97acb32-123-Spec-00040098|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b0-275d-76fd-b531-6149d97acb32","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"13",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"pkalaimo (GVW) - 15/Mar/2024 - LM - Update of specification as per TruVault Document.
1. Updated SMD Reference from TV-SPEC-67180 v1.0 to TV-SPEC-67180 v2.0 for INH, GLO and CHAR Limit Types.
2. Updated Specification Name and Description.
3. Updated Method Reference for BIOASSAY, IC BIOASSAY SAC ST1 and IC BIOASSAY SAC ST2 parameter lists.",,,pkalaimo,tshah1,Reviewed/Approved.,TV-SPEC-67180,Fri Mar 22 05:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b0-4167-7d54-b3ca-be4f49d43d5b-123-Spec-00040113|16|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b0-4167-7d54-b3ca-be4f49d43d5b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|16|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"16",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"MVarghee (GVW) - 22/May/2024  - Update of Specification report as per LCRF.
1. Updated worksheet template for the parameter list BIOASSAY 1 and BIOASSAY 15.
2. Updated method reference for the parameter list BIOASSAY 15.

",,,MVarghee,mari1,Reviewed and Approved,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri May 24 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b0-6c82-78c6-b98f-1459b9bbd59b-123-Spec-00040098|16|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b0-6c82-78c6-b98f-1459b9bbd59b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|16|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"16",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"pkalaimo (GVW) - 10/Jun/2024 - Update of Specification as per LCRF.
1. Replaced DILUTION SEC HPLC C with SAMPLE DILUTION 3C parameter list.
",,,pkalaimo,Lwiertzb,Review and approval GQS by LCRF,TV-SPEC-67180,Tue Jun 11 08:28:06 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b1-35c1-7439-a511-24bb641dbc8e-123-Spec-00040113|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b1-35c1-7439-a511-24bb641dbc8e","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"2",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE,"21JUN2023 nchadwi2 (GQS) - updated threshold per LCRF and ADSI supplementary information.",,,nchadwi2,WVeen1,addition/update LOQs per LCRF and AD-SI supplementary info,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jun 21 10:28:08 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b1-9c9c-773a-a8fe-f5db432f3fa8-123-Spec-00040113|18|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b1-9c9c-773a-a8fe-f5db432f3fa8","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|18|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"18",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"lwerner3(SH) - 16-Jun-2024 - Schaffhausen Pharma Request Form: eFORM-SCH_2024-06-11_Reto Glaus_Due Date 2024-06-26_LM
Removal of Leiden as backup lab from the Amivantamab SC specification
Remove Technique of BIOASSAY + BIOASSAY 15 + BIOASSAY 1 + PH20 ACTIVITY
Update WS for BIOASSAY to 4424_S_adccrtp
Update WS for BIOASSAY 1 to 4424_S_cmet
Update WS for BIOASSAY 15 to 4424_S_adcc
Update WS for PH20 ACTIVITY to 4424_S_ph20_act
",,,lwerner3,sademosk,eFORM-SCH_2024-06-11_Reto Glaus_Due Date 2024-06-26_LM,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jun 19 11:41:22 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b2-0bee-7586-9712-820abf0bf844-123-Spec-00026801|4|8N 14NC|DIL HIC REAGENTS : Component 15|INH|>=|10.0|||UL","019276b2-0bee-7586-9712-820abf0bf844","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00026801|4|8N 14NC|DIL HIC REAGENTS : Component 15|INH|>=|10.0|||UL,Spec-00026801,"4","SPECIFICATION FOR LME: EL-LB-HICHPLC-CNTO4424 (SHARED - LB, SC)",C,"SPECIFICATION FOR LME: EL-LB-HICHPLC-CNTO4424 (SHARED - LB, SC)","22/Nov/2023 - sshank28 (GVW) - Update of Specification report as per LCRF.
1. Added parameter list INCUBATION TIME C.
2. Updated Method Reference for parameter list WL-HIC-REFSTD.",,,sshank28,sademosk,As per LCRF,,Sun Nov 26 14:37:00 EST 2023,DIL HIC REAGENTS,Component 15,DIL HIC REAGENTS : Component 15,INH,>= 10.0,,uL,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b2-0bee-7a67-a71f-9f3a0d38eacb-123-Spec-00026801|3|8N 14NC|DIL HIC REAGENTS : Component 15|INH|>=|10.0|||UL","019276b2-0bee-7a67-a71f-9f3a0d38eacb","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00026801|3|8N 14NC|DIL HIC REAGENTS : Component 15|INH|>=|10.0|||UL,Spec-00026801,"3","SPECIFICATION FOR LME: EL-LB-HICHPLC-CNTO4424 (SHARED - LB, SC)",A,"SPECIFICATION FOR LME: EL-LB-HICHPLC-CNTO4424 (SHARED - LB, SC)","spetrasc - 11.FEB.22

ETS#2061091
Added "" (SHARED - LB, SC)"" Description and name.
Added Site Schaffhausen to Parameter DIL HIC REAGENTS (v1) 8N 14NC",,,spetrasc,nsatzing,ETS2061091,,Mon Feb 21 06:00:00 EST 2022,DIL HIC REAGENTS,Component 15,DIL HIC REAGENTS : Component 15,INH,>= 10.0,,uL,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b2-6294-7e5b-be4f-7fcd02ed588f-123-Spec-00043112|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b2-6294-7e5b-be4f-7fcd02ed588f","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"5","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","30SEP24 TSHAH1 (QCOps) - Per LCRF,
(1) Removed Unit N/A of Component Sample Method ID, Sample pH  and Sample Endpoint of IC PH MEASUREMENT (v1) 2TEXT 3N parameter list.
(2) Updated CoA Translation of IC PH MEASUREMENT (v1) 2TEXT 3N parameter list.
",,,tshah1,mari1,Reviewed and Approved,TV-SPEC-69985,Mon Sep 30 15:14:40 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b2-7d41-7a8c-bcc3-df3928da41a4-123-Spec-00039784|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b2-7d41-7a8c-bcc3-df3928da41a4","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"12",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"PKuruva (GVW) - 02/Jul/2024 - CC 980841 + TASK000025155805 - Update of Specification as per LCRF.
1. Added CDS Name and CDS Interface for SE-HPLC parameter list.

",,,pkuruva,SKuijla2,GQS Reviewed/Approved,TV-SPEC-67179,Tue Jul 09 09:03:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b2-a370-7a09-b66f-3bfd0e58f8fb-123-Spec-00040098|18|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b2-a370-7a09-b66f-3bfd0e58f8fb","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|18|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"18",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"MSriniv4- 27-Aug-2024 - CAPA 001651- Color of Solution by Instrument-Updated Specification
-To include the parameter list IC COLOR INST SAMPLE-3NC 3T 3L.
-To replace method reference from TV-SOP-41700, TV-TMD-00748, TV-TMD-34698  to   TV-SOP-41700, TV-TMD-00748 for the parameter list COLOUR SOLUTION-3LIST

",,,msriniv4,SKuijla2,GQS Reviewed/Approved,TV-SPEC-67180,Thu Sep 12 08:23:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b2-bd59-730e-89f5-2e509746ec50-123-Spec-00043114|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b2-bd59-730e-89f5-2e509746ec50","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"3",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,A,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"30SEP24 TSHAH1 (QCOps) - Per site request, added following parameter lists for Phase 3 limits for Cork JSC,
DNA 1 (v1) 1N, 
HOST CELL PROTEIN 1 (v1) 1N 1TEXT, and 
ELISA 1 (v1) 1N 1TEXT.

",,,tshah1,Mcolli34,Reviewed/Approved,TV-SPEC-69986,Tue Oct 01 09:58:08 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-0a8c-7938-8a64-5ddcee78d1da-123-Spec-00040113|23|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-0a8c-7938-8a64-5ddcee78d1da","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|23|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"23",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"14-Aug-2024 lwerner3 (SC) - updated Spec-00040113 according to LCRF + CC#2330258

1. Changed the CoA translation for Parameter IC SUBVIS 11 (Parameter ID: ""Target Fill Volume"") as following: ""Target Fill Volume [mL]"" to ""Nominal Fill Volume""
2. Change Template for the BIOASSAY 15 from 4424_S_adcc to 4424_S_adccrtp
3. Change Template for the BIOASSAY from 4424_S_adccrtp to 4424_S_adcc


",,,lwerner3,tlinack,ETS 2330258+LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Thu Aug 15 10:01:43 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-100a-7d67-b225-d191c0ac0481-123-Spec-00040098|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-100a-7d67-b225-d191c0ac0481","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"10",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"tyasmeen (GVW) - 31/Jan/2024 - LM - CC 2267208 - Update of specification as per LCRF.
1. Removed NEW PEAKS and NEW PEAKS 1 Parameter lists from Mapping on Parameter section.
2. Added CDS Exclude for Parameter “Component 2 and Component 3” of CSDS NON-REDUCED Parameter and “Component 3” of CSDS REDUCED Parameter lists.",,,tyasmeen,Lwiertzb,Review and approval GQS by LCRF,TV-SPEC-67180,Thu Feb 01 10:32:13 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-100b-7a4b-a8c9-a57d9db8f25f-123-Spec-00040098|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-100b-7a4b-a8c9-a57d9db8f25f","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"9",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"dpriyada (GVW) - 17/Jan/2024 - LM - Update of specification as LCRF.
1. Updated Display Format and Unit for parameters ""Unknown 1"" and ""Unknown 2"" of CIEF UNKNOWN parameter list.",,,dpriyada,mari1,Reviewed and Approved,TV-SPEC-67180,Wed Jan 17 15:01:36 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-20e0-74e1-82cf-362011942eb2-123-Spec-00040113|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-20e0-74e1-82cf-362011942eb2","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"7",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE,"22-Nov-2023-tlinack (SC)-LCRF - Updated Specification to replace parameter lists
1. Removed limit on INT Limit Type for IC PH MEASUREMENT (v1) 2TEXT 3N, Component Sample Endpoint",,,tlinack,Mcolli34,Reviewed/Approved,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Nov 22 15:32:39 EST 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-a4ff-79b0-910c-e9a1e5924a7d-123-Spec-00040113|17|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-a4ff-79b0-910c-e9a1e5924a7d","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|17|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"17",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"RKrish50(GVW) - 29-May-2024 - Schaffhausen Pharma - ETS# 2338885 - Update of Specification
1. To replaced the Parameter List ID IC COLOR INST SAMPLE - 1NC 3TC 3T 3L version 1 by version 2.

MVarghee (GVW) - 28/May/2024 - No changes made to this version.",,,MVarghee,tlinack,ETS# 2338885 ,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed May 29 16:09:34 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-a4ff-7fda-b9d0-0262fe41e757-123-Spec-00040113|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-a4ff-7fda-b9d0-0262fe41e757","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"1",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE,"09/Jun/2023 - tlinack (SC)
First version per TV-SPEC-67180 v1.0 and TV-VAL-256281 v2.0 according to ETS# 2078318",,,ARajmoh1,sademosk,ETS 2078318,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jun 21 07:18:27 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-af56-7e2c-9ef3-d4bc11b2e8b3-123-Spec-00043114|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-af56-7e2c-9ef3-d4bc11b2e8b3","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"1",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,A,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"pkalaimo (GVW) - 07/Aug/2024 - Upload of specification as per TruVault Document.


",,,pkalaimo,nchadwi2,GQS Review/Approval,TV-SPEC-69986,Tue Aug 20 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b3-c1e9-7858-875a-b8f5caf7af55-123-Spec-00040113|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b3-c1e9-7858-875a-b8f5caf7af55","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"3",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE,"21JUN2023 nchadwi2 (GQS) - updated display format of component ""Protein Conc"" of IC A280 SAMPLE (v1) 6N 4NC.  Updated thresholds of CIEF and CSDS NON-REDUCED TESTS to align with LCRF from ADSI.",,,nchadwi2,tlinack,update LOQs per LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jun 21 13:32:14 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b5-3386-7912-8292-ddd1b819ff96-123-Spec-00024855|3|25N|OLIGOSACCHARIDE MAP : Component 15|GLO|>|-99999|||%","019276b5-3386-7912-8292-ddd1b819ff96","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00024855|3|25N|OLIGOSACCHARIDE MAP : Component 15|GLO|>|-99999|||%,Spec-00024855,"3",JNJ 61186372 (CNTO4424) Phase 1b/2a FB Acceptance Criteria for MM# 307511,A,JNJ 61186372 (CNTO4424) Phase 1b/2a FB Stability Protocol and Acceptance Criteria for MM# 307511 Batches,TASK000017510105 amchugh2 15APR19  > Updated SMD reference to Version 3.0  > Replaced CSDS REDUCED (v1) CNTO4424 2N 1LIST with CSDS REDUCED 1 (v1) 3N 1LIST  > Updated CIEF (v1) 9N 1LIST 5 criteria  > Replaced OLIGOSACCHARIDE (v1) 1TEXT with OLIGOSACCHARIDE (v1) 25N  >Updated Display Format for POLYSORBATE (v1) 1 PCT,,,amchugh2,joconn40,,TV-TEC-100387,Mon Apr 29 11:57:40 EDT 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,GLO,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b5-8bae-715d-99cb-a9edb0d1d530-123-Spec-00040098|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b5-8bae-715d-99cb-a9edb0d1d530","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"1",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"25/May/2023 - dpriyada (GVW) - Upload of specification as per TruVault Document.
20JUN2023 wveen1 (GQS) aligned CoA translations with release Spec-00040113 v1",,,dpriyada,nchadwi2,GQS Review/Approval,TV-SPEC-67180,Wed Jun 21 15:36:16 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b6-0903-7216-b343-6645070c54c5-123-Spec-00040113|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b6-0903-7216-b343-6645070c54c5","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"8",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,"SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE - (SHARED LB, SC)","30/Nov/2023 - dpriyada (GVW) - Update of specification as per LCRF.
1. Updated DP for parameter ""Component 2"" of BIOASSAY 2 parameter list.
2. Updated Specification Name.",,,dpriyada,nchadwi2,GQS Review/Approval,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri Dec 01 10:44:06 EST 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b6-0903-7d08-82aa-6ae75e4a1f52-123-Spec-00040113|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b6-0903-7d08-82aa-6ae75e4a1f52","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"14",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"03/May/2024 - tlinack(SC) - Update of specification report.
1. Update SMD Reference from TV-TEC-250649 v3.0 to TV-TEC-250649 v4.0 at INH and IPC Limit Type


",,,tlinack,lwerner3,updated to TV-TEC-250649 v4.0,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Mon May 06 11:06:31 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b6-e087-7c05-b562-131be1259a3b-123-Spec-00040098|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b6-e087-7c05-b562-131be1259a3b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"3",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"28/Aug/2023 - pkalaimo (GVW) - Update of specification as per LCRF.
1. Added INT Limit Type.
2. Added IC SUBVIS 11 parameter list.
04SEP2023 wveen1 (GQS) set pending approval",,,pkalaimo,nchadwi2,GQS Review/Approval,TV-SPEC-67180,Mon Sep 04 17:25:29 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b7-297e-703a-ba36-b8490ce67f9d-123-Spec-00040113|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b7-297e-703a-ba36-b8490ce67f9d","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"12",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"04-Apr-2024 tlinack (SC) - Update of specification report as per LCRF
1. Updated Templates as per Memo TV-TEC-288561on BIOASSAY + BIOASSAY 15 + BIOASSAY 1 + PH20 ACTIVITY
2. Update Technique of BIOASSAY + BIOASSAY 15 + BIOASSAY 1 + PH20 ACTIVITY to ""LBFPT»
3. Update SMD reference from TV-SPEC-67180 v2.0, TV-VAL-256281 v2.0 to TV-SPEC-67180 v2.0, TV-TEC-250649 v3.0 on the INH limit type
4. Update SMD reference from TV-VAL-256281 v2.0 to TV-TEC-250649 v3.0 on the IPC limit type",,,tlinack,sademosk,As per LCRF - eFORM-SCH_2024-04-02_Reto Glaus_Due Date 2024-04-09_LM,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri Apr 05 09:46:04 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b7-2b7b-7a77-aefb-33b5c71e683c-123-Spec-00040098|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b7-2b7b-7a77-aefb-33b5c71e683c","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"6",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"09OCT2023 nchadwi2 (GQS) - per site LCRF - added OD280 C",,,nchadwi2,WVeen1,approved changes per LCRF,TV-SPEC-67180,Mon Oct 09 15:10:03 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b7-6548-7429-a8ed-5124011b56e6-123-Spec-00023860|7|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276b7-6548-7429-a8ed-5124011b56e6","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00023860|7|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00023860,"7","JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B",A,"JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B Acceptance Criteria",TASK000018098914 loriord2 Cork_API-L 22Aug19- Replaced CIEF (v1) 9N 1LIST 4 with CIEF (v1) 8N 1LIST 6,,,loriord2,loconno5,,,Tue Sep 03 15:17:24 EDT 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b7-90d0-738b-8c8c-11949c989b19-123-Spec-00040113|20|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b7-90d0-738b-8c8c-11949c989b19","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|20|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"20",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"08-Jul-2024 tlinack (SC) - Update of Specification report as per LCRF (ETS 2295290).
1. Updated SMD Refrence from TV-SPEC-67180 v3.0, TV-TEC-250649 v4.0 to TV-SPEC-67180 v3.0, TV-VAL-278811 v1.0 for the INH limit type.
2. Updated SMD Refrence from TV-TEC-250649 v4.0 to TV-VAL-278811 v1.0 for the IPC limit type.",,,tlinack,lwerner3,"update according to LCRF, ETS 2295290","TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jul 10 14:07:56 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b7-d100-7e5c-87a5-82dd992b144b-123-Spec-00043114|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b7-d100-7e5c-87a5-82dd992b144b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"2",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,A,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"RDhanas2 (GVW) - 24/Sep/2024 - Update of specification as per LCRF.
1. Added IC PH MEASUREMENT, IC A280 SAMPLE, IC CMET BIND SAC, IC ENDTOX SAMPLE,
IC BIOASSAY SAC ST1, CIEF 1, and BIOBURDEN parameter lists.
29SEP24 TSHAH1 (QCOps) - Per LCRF, added following parameter lists for Cork JSC.
COLOR OF SOLUTION 1 (v1) 3LIST, CIEF UNKNOWN 1 (v1) 3U - 1TEXT 2N, DOT BLOT IDENTITY 1 (v1) 1LIST 3, IDENTITY 6 (v1) 1LIST, BINDING ASSAY (v1) 2N, BINDING ASSAY 1 (v1) 2N, SE-HPLC 1 (v1) 3N, CSDS REDUCED 1 (v1) 2N 1LIST 15, NEW PEAKS 2 (v1) 3U, IMPURITY (v1) 3U, CSDS NON-REDUCED 1 (v1) 2N 1LIST 16, NEW PEAKS 3 (v1) 3U, IMPURITY 3 (v1) 3U, HI HPLC 1 (v1) 3N, OLIGOSACCHARIDE MAP2 (v1) 8N, BIOBURDEN (v1) 3N, BIOASSAY 3 (v1) 2N, and MULTI ATTR PEP MAP 1 (v1) 5N.",,,rdhanas2,Mcolli34,Reviewed/Approved,TV-SPEC-69986,Mon Sep 30 12:41:08 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b7-ecf8-730d-b536-58493b63f32e-123-Spec-00039784|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b7-ecf8-730d-b536-58493b63f32e","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"9",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"Comullan Cork_API-L 19MAR2024 -> Opened in error

dpriyada (GVW) - 20/Mar/2024 - LM - Update of specification as per TruVault Document.
1. Updated Specification Name and Description.
2. Updated SMD Reference from TV-SPEC-67179 v1.0 to TV-SPEC-67179 v2.0 for all Limit Types.
3. Updated Method Reference for BIOASSAY, BIOASSAY 2, BIOBURDEN and IC ENDTOX SAMPLE parameter lists.
4. Updated CoA Group for OLIGOSACCHARIDE MAP parameter list.
5. Added CoA Group and Updated CoA Translation for GLYCATION parameter list.
6. Added CoA Group for SUBUNIT MASS parameter list.",,,COmullan,tshah1,Reviewed/Approved.,TV-SPEC-67179,Fri Mar 22 05:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b8-3561-7d94-b261-23f47373ec93-123-Spec-00043112|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b8-3561-7d94-b261-23f47373ec93","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"4","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","27SEP24 TSHAH1 (QCOps) - Per LCRF,
(1) Added INT Limit Type.
(2) Reorder all Limit Types.
(3) Added  IC PH MEASUREMENT (v1) 2TEXT 3N parameter list.
(4) Updated Template of PH (v1) 1 parameter list.
",,,tshah1,mari1,Reviewed and Approved,TV-SPEC-69985,Fri Sep 27 18:13:51 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b8-57d5-7b87-9c19-2dfda2383732-123-Spec-00040098|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b8-57d5-7b87-9c19-2dfda2383732","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"4",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"26SEP2023 nchadwi2 (GQS) - per site LCRF - adjusted CoA Translation and INH limit to reflect 1.40 for IC A280 SAMPLE, 6N 4NC - component Absorptivity Const.",,,nchadwi2,tshah1,Reviewed and Approved.,TV-SPEC-67180,Tue Sep 26 12:03:00 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b8-9875-7cdf-ba72-82d4398af090-123-Spec-00040113|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b8-9875-7cdf-ba72-82d4398af090","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"9",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,"SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE - (SHARED LB, SC)","pkalaimo (GVW) - 05/Feb/2024 - LM - Update of specification as per LCRF.
1. Replaced CIEF - 7N 1LIST 4 with CIEF - 8N 1LIST parameter list.",,,pkalaimo,mari1,Reviewed and Approved,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Thu Feb 08 14:06:28 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276b9-ba2a-76fa-846b-714fdc4565db-123-Spec-00039784|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276b9-ba2a-76fa-846b-714fdc4565db","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"13",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"PKuruva (GVW) - 11/Jul/2024 - CC 980841 + TASK000025155805 - Update of Specification as per LCRF.
1. Updated CoA Translation for SE-HPLC parameter list.
",,,pkuruva,Lwiertzb,Review and approval GQS by LCRF,TV-SPEC-67179,Fri Jul 12 09:00:48 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ba-912c-7624-a442-c94006a1f5c2-123-Spec-00040113|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ba-912c-7624-a442-c94006a1f5c2","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"10",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE - (SC),"14/Feb/2024 - sshank28 (GVW) - Schaffhausen - ETS CC 2162510 - Updated the Specification report as per LCRF.
1. Updated Worksheet template for parameter list PEPTIDE MAPPING 1.
2. Updated Specification Name.
3. Updated INT limits for parameters Sample Temp and Sample Endpoint of parameter list IC PH MEASUREMENT.
4. Removed parameter lists COLOUR SOLUTION- 3LIST, TURBIDITY 1 - 1N, CIEF - 8N 1 LIST, CIEF UNKNOWN - 3U - 1TEXT 2N, PARTICULATE MATTER 6 - 8N, PARTICULATE MATTER 1- 6N , IC A280 SAMPLE 1 - 6N 4NC, OD280 C - 5N 3NC, BIOASSAY - 2N, BIOASSAY 1 - 2N, PH20 ACTIVITY 1 - 1N, SE-HPLC - 3N, CSDS REDUCED - 2N 1LIST 3, NEW PEAKS - 1U, IMPURITY - 1U, CSDS NON-REDUCED - 2N 1LIST 1, NEW PEAKS 1 - 1U, IMPURITY 1 - 1U, BIOASSAY 2 - 2N, MULTI ATTR PEP MAP - 5N, POLYSORBATE 80 1 - 1N, MICRO ID LM - 3 COMP 2 LIST 1 TEXT, DIL CSDS R C12 - 1N 1LIST 4NC, DIL CSDS NR C11 - 1N 1LIST 4NC, DIL REF CIEF C - 1N 1LIST 6NC, DILUTION SEC HPLC C - 2N 4NC, VOLUME VAR C - 2N 1NC, VOLUME VAR C1 - 2N 1NC, OSMOLALITY - 1N, DOT BLOT IDENTITY - 1LIST 3 
5. Removed site Leiden_API-L from parameter Lists IC PH MEASUREMENT, POLYSORBATE 80, PEPTIDE MAPPING - 15N, IC SUBVIS 11 - 3N 8NC 5DATE 1T 1L and ID HUPH20 SAMPLE C - 3L 2NC.
6. Removed CoA Limit text for parameter Sample Temp of parameter list IC PH MEASUREMENT.
7. Added parameter list EMS BATCHLINKING to parameter list section.
",,,sshank28,tlinack,ETS 2162510 + LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Thu Feb 15 16:50:43 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276ba-b1f2-70c7-a7ba-df228325c196-123-Spec-00043112|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276ba-b1f2-70c7-a7ba-df228325c196","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|3|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"3","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","20SEP24 TSHAH1 (QCOps) - Per LCRF, Updated Template for the following parameter lists:
CIEF (v1) 7N 1LIST 4 
CIEF UNKNOWN (v1) 3U - 1TEXT 2N 
BIOASSAY (v1) 2N
BIOASSAY 1 (v1) 2N
SE-HPLC (v1) 3N
CSDS REDUCED (v1) 2N 1LIST 3
NEW PEAKS (v1) 1U
IMPURITY (v1) 1U
BIOASSAY 2 (v1) 2N

",,,tshah1,mari1,Reviewed and Approved,TV-SPEC-69985,Fri Sep 20 18:02:22 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bb-0cec-7a9f-ae4f-c02d20efee52-123-Spec-00040113|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bb-0cec-7a9f-ae4f-c02d20efee52","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"15",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"15/May/2024 - tlinack(SC) - Update of specification report as per ETS 2295290 and LCRF.
1. Update SMD Reference from TV-SPEC-67180 v2.0 to TV-SPEC-67180 v3.0 at INH + GLO and CHAR Limit Type
2. Update CoA Translation for IC A280 SAMPLE (v1) 6N 4NC on Component Protein Conc (Standard)
3. Added IC 1X VOLUME 3 (2DATE 3N 2NC) with EL-SC-VOLUME-3 for 15mL vials
4. Added IC 1X VOLUME 4 (2DATE 3N 2NC) with EL-SC-VOLUME-3 for 22mL vials
5. Added LME EL-SC-VFP-22 to parameter IC VFP STG1 (2D 2C 2L) which will be used for 10mL vials
6. Added IC VFP STG1 A (2D 2C 2L) + IC VFP STG2.1 A (1D 2C 2L) + IC VFP STG3.1 A (1D 2C 2L), which will be used for 14mL and 15mL vials
7. Added IC VFP STG1 B (2D 2C 2L) + IC VFP STG2.1 B (1D 2C 2L) + IC VFP STG3.1 B (1D 2C 2L) and PARTICULATE MATTER 8 (v1) 1LIST, which will be used for 22mL vials
8. Update INT Limit of Density for IC 1X VOLUME 1 (v1) 2DATE 3N 2NC and IC 1X VOLUME 2 (v1) 2DATE 3N 2NC as per NC-011692

",,,tlinack,sademosk,ETS# 2295290,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri May 17 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bb-2cf8-752d-9b09-7d4d4a9076f1-123-Spec-00040098|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bb-2cf8-752d-9b09-7d4d4a9076f1","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"15",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"tyasmeen (GVW) – 13/May/2024 – CC 2295290 – Update of Specification as per Truvault Document.
1. Updated SMD Reference from TV-SPEC-67180 v2.0 to TV-SPEC-67180 v3.0 for all applicable limit types.
2. Updated COA Translation for “Protein Conc” of IC A280 SAMPLE parameter list and “Component 7” of OD280 C Parameter list.
",,,tyasmeen,tshah1,Reviewed/Approved.,TV-SPEC-67180,Fri May 17 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bb-67c9-7067-91cb-af8217470bf9-123-Spec-00039784|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bb-67c9-7067-91cb-af8217470bf9","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"10",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"dpriyada (GVW) - 08/Apr/2024 - LM - Update of specification as per LCRF.
1. Updated Worksheet Template for applicable parameter lists.
2. Replaced BIOASSAY 1 with IC CMET BIND SAC parameter list.
3. Replaced BIOASSAY 2 with IC BIOASSAY SAC ST1 parameter list.",,,dpriyada,Mcolli34,Reviewed/Approved,TV-SPEC-67179,Wed Apr 10 16:37:19 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bc-87f1-7815-828c-5bea751a1b5c-123-Spec-00023860|5|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276bc-87f1-7815-828c-5bea751a1b5c","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00023860|5|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00023860,"5","JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B Specification",A,"JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B Stability Protocol and Acceptance  Criteria Specification","TASK0000017487546 amchugh2 10APR19  > Updated SMD reference to Version 3.0  > Replaced OLIGOSACCHARIDE MAP (v1) 1TEXT with OLIGOSACCHARIDE (v1) 25N  > Updated criteria CSDS REDUCED (v1) CNTO4424 2N 1LIST, SE-HPLC (v1) 3N, POLYSORBATE (v1) 1 PCT & HI HPLC (v1) 3N  > Updated OD280 C 1 (v1) 5N 3NC CoA Translation  > Replaced PARTICULATE MATTER 6 (v1) 7N with PARTICULATE MATTER 6 (v1) 8N  >Replaced CIEF (v1) 9N with CIEF (v1) 9N 1LIST 4  > Updated CoA Translation for HI HPLC (v1) 3N  > Removed PARTICULATE MATTER (v1) CNTO4424 1LIST",,,amchugh2,loconno5,,,Wed May 29 14:22:54 EDT 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bc-c2db-7173-8d47-835307e7d2c3-123-Spec-00043100|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bc-c2db-7173-8d47-835307e7d2c3","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043100|1|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043100,"1","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS",E,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS",pkalaimo (GVW) - 06/Aug/2024 - Upload of specification as per TruVault Document.,,,pkalaimo,nchadwi2,GQS Review/approval,TV-SPEC-69985,Tue Aug 20 06:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bd-9db7-7a14-8855-a4ad0f21850a-123-Spec-00043112|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bd-9db7-7a14-8855-a4ad0f21850a","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|2|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"2","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","MSriniv4- 27-Aug-2024 - CAPA 001651- Color of Solution by Instrument-Updated Specification
-To include the parameter list IC COLOR INST SAMPLE-3NC 3T 3L.
-To replace method reference from TV-SOP-41700, TV-TMD-00748, TV-TMD-34698  to   TV-SOP-41700, TV-TMD-00748 for the parameter list COLOUR SOLUTION-3LIST",,,msriniv4,SKuijla2,GQS Reviewed/Approved,TV-SPEC-69985,Thu Sep 12 08:28:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bd-d369-737d-95d2-e1670a2b6c67-123-Spec-00024378|11|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276bd-d369-737d-95d2-e1670a2b6c67","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00024378|11|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00024378,"11",JNJ-61186372 (CNTO 4424) 50 mg/mL Formulated Bulk,A,Specification and Justification of Specifications for Clinical JNJ-61186372 (CNTO 4424) 50 mg/mL Formulated Bulk (Global MM# 309278),TASK000018098914  loriord2 Cork_API-L 21Aug19- Replaced CIEF (v1) 9N 1LIST 4 with CIEF (v1) 8N 1LIST 6  ,,,loriord2,loconno5,,"TV-SPEC-50156, DS-SPE-34672",Tue Sep 03 15:18:03 EDT 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bd-e219-7587-92ed-4a5391c1eb95-123-Spec-00040098|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bd-e219-7587-92ed-4a5391c1eb95","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"12",JNJ-61186372 SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - STAB,"dpriyada (GVW) - 12/Mar/2024 - LM - Update of specification as per LCRF.
1. Updated Worksheet Template for applicable parameter lists.",,,dpriyada,mari1,Reviewed and Approved,TV-SPEC-67180,Thu Mar 14 21:18:39 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276be-1915-7e5c-97f6-2a2c025069d4-123-Spec-00040113|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276be-1915-7e5c-97f6-2a2c025069d4","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"6",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE,"03-Nov-2023-MSriniv4(GVW)-ETS 2296937-Updated Specification to replace parameter lists- IC VFP STG2 -1D 2C 2L with IC VFP STG2.1-1D 2C 2L    and IC VFP STG3-1D 2C 2L with IC VFP STG3.1-1D 2C 2L.",,,msriniv4,tlinack,ETS 2296937,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Tue Nov 14 06:00:00 EST 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276be-379f-717d-8f6e-2bf806df7cb7-123-Spec-00040113|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276be-379f-717d-8f6e-2bf806df7cb7","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"5",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DP,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PROCESS PERFORMANCE QUALIFICATION DRUG PRODUCT - RELEASE,"18Oct2023 Mcolli34 (eLIMS Global) As per Memo TV-TEC-275696, Leiden_API-L added for backup release testing.

1) Added parameters COLOUR SOLUTION 3LIST, TURBIDITY 1 1N, CIEF (v1) 7N 1LIST 4, CIEF UNKNOWN (v1) 3U - 1TEXT 2N, PARTICULATE MATTER 6 (v1) 8N, PARTICULATE MATTER 1 (v1) 6N , IC A280 SAMPLE 1 (v1) 6N 4NC, OD280 C (v1) 5N 3NC, BIOASSAY (v1) 2N, BIOASSAY 1 (v1) 2N, PH20 ACTIVITY 1 (v1) 1N, SE-HPLC (v1) 3N, CSDS REDUCED (v1) 2N 1LIST 3, NEW PEAKS (v1) 1U, IMPURITY (v1) 1U, CSDS NON-REDUCED (v1) 2N 1LIST 1, NEW PEAKS 1 (v1) 1U, IMPURITY 1 (v1) 1U, STERILITY (v1) 1LIST 1, 
BIOASSAY 2 (v1) 2N, MULTI ATTR PEP MAP (v1) 5N, POLYSORBATE 80 1 (v1) 1N, MICRO ID LM (v1) 3 COMP 2 LIST 1 TEXT, DIL CSDS R C12 (v1) 1N 1LIST 4NC, DIL CSDS NR C11 (v1) 1N 1LIST 4NC, DIL REF CIEF C (v2) 1N 1LIST 6NC, DILUTION SEC HPLC C (v2) 2N 4NC for site Leiden_API-L

2) Added site Leiden_API-L to parameters IC PH MEASUREMENT, POLYSORBATE 80 1N, PEPTIDE MAPPING (v1) 15N, IC SUBVIS 11 (v1) 3N 8NC 5DATE 1T 1L

3) Updated INT limits for parameter IC PH MEASUREMENT (v1) 2TEXT 3N",,,Mcolli34,tshah1,Reviewed and Approved.,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Oct 18 21:22:00 EDT 2023,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bf-150c-7cdf-b487-4bfe8f1adbfe-123-Spec-00023860|8|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%","019276bf-150c-7cdf-b487-4bfe8f1adbfe","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00023860|8|25N|OLIGOSACCHARIDE MAP : Component 15|CHAR|>|-99999|||%,Spec-00023860,"8","JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B",A,"JNJ-61186372, CNTO 4424 FVP Development 50mg/ml Formulation B Acceptance Criteria","loriord2 Cork_API-L 25Nov19-  > Updated Method References for TURBIDITY (v1) 1 NTU, CSDS REDUCED (v1) CNTO4424 2N 1LIST, CSDS NON REDUCED (v1) CNTO4424 2N 1LIST, SE-HPLC (v1) 3N, CIEF (v1) 7N 1LIST 4, OD280 C1 (v1) 5N 3NC and BIOASSAY 13 (v1) 2N  > Replaced CIEF (v1) 8N 1LIST 6 with CIEF (v1) 7N 1LIST 4 ",,,loriord2,loconno5,,,Tue Nov 26 15:20:41 EST 2019,OLIGOSACCHARIDE MAP,Component 15,OLIGOSACCHARIDE MAP : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bf-2c3c-7f7e-ba9a-e108bf0c5e1b-123-Spec-00040113|25|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","019276bf-2c3c-7f7e-ba9a-e108bf0c5e1b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|25|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"25",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"25-Sept-2024 tlinack (SC) - Update of specification as per ETS 2295290+2370055
1. Update SMD Reference from TV-TEC-250649 v4.0 to TV-TEC-250649 v5.0 at the INH and IPC 2 Limit Type",,,tlinack,lwerner3,lwerner3 - 27-Sep-2024 - ETS: 2295290 + 2370055  ,"TV-SPEC-67180, TV-SPEC-54413, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-61505, TV-SPEC-66430, TV-SPEC-69985",Fri Sep 27 09:38:12 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bf-3763-7264-ba71-5cb8694f92b2-123-Spec-00040113|25|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bf-3763-7264-ba71-5cb8694f92b2","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|25|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"25",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"25-Sept-2024 tlinack (SC) - Update of specification as per ETS 2295290+2370055
1. Update SMD Reference from TV-TEC-250649 v4.0 to TV-TEC-250649 v5.0 at the INH and IPC 2 Limit Type",,,tlinack,lwerner3,lwerner3 - 27-Sep-2024 - ETS: 2295290 + 2370055  ,"TV-SPEC-67180, TV-SPEC-54413, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-61505, TV-SPEC-66430, TV-SPEC-69985",Fri Sep 27 09:38:12 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bf-4206-73df-8168-a4a182009ce5-123-Spec-00040113|25|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","019276bf-4206-73df-8168-a4a182009ce5","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|25|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"25",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"25-Sept-2024 tlinack (SC) - Update of specification as per ETS 2295290+2370055
1. Update SMD Reference from TV-TEC-250649 v4.0 to TV-TEC-250649 v5.0 at the INH and IPC 2 Limit Type",,,tlinack,lwerner3,lwerner3 - 27-Sep-2024 - ETS: 2295290 + 2370055  ,"TV-SPEC-67180, TV-SPEC-54413, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-61505, TV-SPEC-66430, TV-SPEC-69985",Fri Sep 27 09:38:12 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019276bf-42d6-7762-9832-632eae9ebeb4-123-Spec-00039784|16|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019276bf-42d6-7762-9832-632eae9ebeb4","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|16|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"16",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"PKuruva (GVW) - 13/Aug/2024 - Update of specification as per LCRF.
1. Updated CoA Translation for SE-HPLC parameter list.",,,pkuruva,tshah1,Reviewed/Approved.,TV-SPEC-67179,Mon Aug 19 12:12:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0192b73a-9a7a-785d-9bdf-e31867a7a77d-123-Spec-00043112|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0192b73a-9a7a-785d-9bdf-e31867a7a77d","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"6","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","22-OCT-2024 - NC10(GVW) - NC-022573-Updated Specification
-To replace the parameter list BIOASSAY-2N with IC BIOASSAY SAC ST1-1LIST 13N 1NC and IC BIOASSAY SAC ST2-1LIST 11N 14NC
-To replace the parameter list BIOASSAY 1-2N with IC CMET BIND SAC-7N 1NC
-To replace the Parameter list SUBVIS-10N 2LIST 6NC 4DATE with PARTICULATE MATTER 1-6N
-To update the LME Templatefor  CSDS NON-REDUCED-2N 1LIST 1, IMPURITY 1-1U, NEW PEAKS1-1U with EL-LB-CSDSNON-CNTO4424-Gen2
-To add technique as Gel Electrophoresis for CSDS NON-REDUCED-2N 1LIST 1.",,,NC10,Mcolli34,Reviewed/Approved as per LCRF,TV-SPEC-69985,Thu Oct 24 02:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-0192b73a-9af5-7d28-94c1-3739e5e142cf-123-Spec-00040098|19|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0192b73a-9af5-7d28-94c1-3739e5e142cf","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|19|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"19",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"22-OCT-2024 - NM29(GVW) - NC-022573 - Updated specification
-To add Worksheet ID WL-LB-PEPMAP-CNTO4424 and to Remove LME template EL-LB-MAMMAMID-CNTO4424-Gen2.
",,,NM29,Mcolli34,Reviewed/Approved as per LCRF,"TV-SPEC-69985, TV-SPEC-67180",Thu Oct 24 02:00:00 EDT 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-0192b73a-9b1b-7938-ac0a-a5312662be6e-123-Spec-00040113|26|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0192b73a-9b1b-7938-ac0a-a5312662be6e","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|26|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"26",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 22/Oct/2024 - ETS CC 2339662 - Update of specification report as per LCRF.
1. Replaced parameter list IC DOTBLOT SAMPLE with IC DOTB SAMPLE CONC.
2. Replaced parameter list IC A280 SAMPLE with IC A280 SAMPLE CONC.

",,,Gchokkal,lwerner3,Correction #2339662 / LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Thu Nov 07 00:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0192b73a-9c3a-7eda-8dde-0deb6938e802-123-Spec-00040113|26|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","0192b73a-9c3a-7eda-8dde-0deb6938e802","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|26|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"26",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 22/Oct/2024 - ETS CC 2339662 - Update of specification report as per LCRF.
1. Replaced parameter list IC DOTBLOT SAMPLE with IC DOTB SAMPLE CONC.
2. Replaced parameter list IC A280 SAMPLE with IC A280 SAMPLE CONC.

",,,Gchokkal,lwerner3,Correction #2339662 / LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Thu Nov 07 00:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0192b73a-9cc1-7797-8e3e-596f33d65386-123-Spec-00040113|26|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","0192b73a-9cc1-7797-8e3e-596f33d65386","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|26|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"26",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 22/Oct/2024 - ETS CC 2339662 - Update of specification report as per LCRF.
1. Replaced parameter list IC DOTBLOT SAMPLE with IC DOTB SAMPLE CONC.
2. Replaced parameter list IC A280 SAMPLE with IC A280 SAMPLE CONC.

",,,Gchokkal,lwerner3,Correction #2339662 / LCRF,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Thu Nov 07 00:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019342c5-8c2e-7c6d-9556-a70f68fb616f-123-Spec-00043114|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019342c5-8c2e-7c6d-9556-a70f68fb616f","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|4|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"4",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,A,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"15NOV2024 nchadwi2 (GQS) - Per site request ""2024-11-15_TV-eFRM-10818 eLIMS CoE Master Data Request Input Form - signed- For Ticket 6332""
1. Updated CoA translation for IC A280 SAMPLE (v1) 6N 4NC component ""Protein Conc (Standard)""",,,nchadwi2,Mcolli34,Reviewed/Approved as per LCRF,TV-SPEC-69986,Fri Nov 15 12:05:01 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019342c5-e000-721f-936c-e187ddcb8f0b-123-Spec-00043112|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019342c5-e000-721f-936c-e187ddcb8f0b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"7","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","29-OCT-2024 - NM29(GVW) - Update Specification 
- To Add the Parameter list ID IC TURB AVG CV VERIF - 7N 7NC 
- To Add the LME Template EL-LB-Turbidity-Multiproduct for IC TURB AVG CV VERIF - 7N 7NC 
- To Add the Technique Visual inspection for IC TURB AVG CV VERIF - 7N 7NC
04-NOV-2024 - NM29(GVW) - Update Specification
- To Add the Parameter list ID IC SUBVIS 12 - 4N 8NC 5DATE 1TEXT
- To Add the LME Template EL-LB-SUBVIS New for ID IC SUBVIS 12 - 4N 8NC 5DATE 1TEXT
-To include GLO limit type for IC SUBVIS 12 - 4N 8NC 5DATE 1TEXT to populate the reporting components",,,NM29,SKuijla2,GQS Reviewed/Approved,TV-SPEC-69985,Wed Nov 13 15:04:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019342c5-e6f1-7e46-83d2-fa72da9362fb-123-Spec-00040113|27|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019342c5-e6f1-7e46-83d2-fa72da9362fb","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|27|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"27",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 11/Nov/2024 - ETS CC 2332614 - Update of specification report as per LCRF.
1. Removed parameter list IC SUBVIS 11.
2. Added parameter lists IC SUBVIS 12 for 10mL Vial /SP-70 2282024-0 / SP-70 1352024-1
3. Added parameter lists IC SUBVIS 12 A for 14mL Vial /SP-70 2292024-3 / SP-70 1652023-1
4. Added parameter lists IC SUBVIS 12 B for 15mL Vial /SP-70 1352024-0
5. Added parameter lists IC SUBVIS 12 C for 22mL Vial /SP-70 1352024-1
",,,Gchokkal,lwerner3,ETS CC 2332614,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-71673, TV-SPEC-61505",Thu Nov 21 14:47:08 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019342c5-e7d8-784a-a80c-735ae29afa0f-123-Spec-00040113|27|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","019342c5-e7d8-784a-a80c-735ae29afa0f","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|27|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"27",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 11/Nov/2024 - ETS CC 2332614 - Update of specification report as per LCRF.
1. Removed parameter list IC SUBVIS 11.
2. Added parameter lists IC SUBVIS 12 for 10mL Vial /SP-70 2282024-0 / SP-70 1352024-1
3. Added parameter lists IC SUBVIS 12 A for 14mL Vial /SP-70 2292024-3 / SP-70 1652023-1
4. Added parameter lists IC SUBVIS 12 B for 15mL Vial /SP-70 1352024-0
5. Added parameter lists IC SUBVIS 12 C for 22mL Vial /SP-70 1352024-1
",,,Gchokkal,lwerner3,ETS CC 2332614,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-71673, TV-SPEC-61505",Thu Nov 21 14:47:08 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019342c5-e864-7e00-8c2e-551deab613e8-123-Spec-00040113|27|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","019342c5-e864-7e00-8c2e-551deab613e8","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|27|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"27",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 11/Nov/2024 - ETS CC 2332614 - Update of specification report as per LCRF.
1. Removed parameter list IC SUBVIS 11.
2. Added parameter lists IC SUBVIS 12 for 10mL Vial /SP-70 2282024-0 / SP-70 1352024-1
3. Added parameter lists IC SUBVIS 12 A for 14mL Vial /SP-70 2292024-3 / SP-70 1652023-1
4. Added parameter lists IC SUBVIS 12 B for 15mL Vial /SP-70 1352024-0
5. Added parameter lists IC SUBVIS 12 C for 22mL Vial /SP-70 1352024-1
",,,Gchokkal,lwerner3,ETS CC 2332614,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-71673, TV-SPEC-61505",Thu Nov 21 14:47:08 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01934d0c-270b-7cd5-839c-769bf3a3aa97-123-Spec-00043112|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01934d0c-270b-7cd5-839c-769bf3a3aa97","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|8|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"8","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","RDhanas2 (GVW) - 20/Nov/2024 - Update of specification as per LCRF.
1. Replaced CIEF - 7N 1LIST 4 with CIEF - 8N 1LIST parameter list.
2. Added DIL REF CIEF C, DIL CSDS NR C11 and DIL CSDS R C12 parameter lists.


",,,rdhanas2,mari1,Reviewed and Approved,TV-SPEC-69985,Tue Nov 26 19:26:33 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-0193712c-82b5-7f45-a657-51823b5a53f6-123-Spec-00040098|20|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0193712c-82b5-7f45-a657-51823b5a53f6","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|20|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"20",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"NC10(GVW) - 28-NOV-2024 - CC# 2056585 - Updated Specification
-To add the parameter list IC TURB AVG CV VERIF-7N 7NC
-To add the parameter list IC SUBVIS 12-4N 8NC 5DATE 1TEXT
-To add LME Template EL-LB-Turbidity-MultiProduct for IC TURB AVG CV VERIF-7N 7NC and EL-LB-SUBVIS New for IC SUBVIS 12-4N 8NC 5DATE 1TEXT
-To add Technique Visual inspection for IC TURB AVG CV VERIF-7N 7NC and Visual inspection for IC SUBVIS 12-4N 8NC 5DATE 1TEXT
",,,NC10,SKuijla2,GQS Reviewed/Approved,"TV-SPEC-67180, TV-SPEC-69985",Fri Dec 06 09:44:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-01939531-3f8d-751a-b12b-eb498c6f0188-123-Spec-00043112|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01939531-3f8d-751a-b12b-eb498c6f0188","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|9|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"9","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","04DEC2024 nchadwi2 (GQS) - updated specification per TruVault update / CC 2387769 and site LCRF ""2024-12-04_TV-eFRM-10818_v9.0 ABOV 28-NOV-24 - signed""
1. Updated SMD references for INH, GLO, PHASE 3, ALERT and CHAR limit types.
2. Updated GLO limits for CIEF (v1) 8N 1LIST	Component 4 and Component 7.
3. Updated GLO limit for PH20 ACTIVITY (v1) 1N.
5. Added PARTICULATE MATTER (v1) CNTO4424 1LIST with GLO limit.
6. Aligned CoA translation and CoA limit text and added GLO limit for OD280 C 1 (v1) 5N 3NC.
7. Removed BIOASSAY 2 (v1) 2N parameterlist.
8. Aligned CoA translation for PEPTIDE MAPPING 1 (v1) 1N.
9. Resequenced
10. Per LCRF updated worksheet template for PARTICULATE MATTER 1 (v1) 6N.
11. Updated CoA translation, CoA limit text, units and dp for IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT component Particles/mL 10-25um and added CHAR limit for same.
12. Added GLO limits for PARTICULATE MATTER 1 (v1) 6N Component 5 and Component 6.

",,,nchadwi2,WVeen1,CC2387769,TV-SPEC-69985,Tue Dec 10 06:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-01939531-5295-7ab8-9385-132785cdcc89-123-Spec-00043114|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01939531-5295-7ab8-9385-132785cdcc89","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|5|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"5",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,A,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"04DEC2024 nchadwi2 (GQS) - updated specification per TruVault update / CC 2387769 
1. Updated SMD references for INH, GLO, PHASE 3, ALERT and CHAR limit types.
2. Updated GLO limits for CIEF (v1) 7N 1LIST 4 - Component 4 and Component 6.
3. Updated GLO limits for CIEF 1 (v1) 7N 1LIST 4 - Component 4 and Component 6.
4.  Removed BIOASSAY 2 (v1) 2N and BIOASSAY 3 (v1) 2N
5. Resequenced",,,nchadwi2,WVeen1,CC2387769,TV-SPEC-69986,Tue Dec 10 06:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01939531-56ca-7e2d-b08c-17073faf6740-123-Spec-00040113|28|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01939531-56ca-7e2d-b08c-17073faf6740","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|28|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"28",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"04/Dec/2024 - tlinack (SC) - Update of specification report.  - ETS 2387769 + 2375655 + ETS 2192559
1. Update SMD from TV-SPEC-69985 v1.0 to TV-SPEC-69985 v2.0 at INH+GLO 1+CHAR 1+ALERT Limit Type
2. Update SMD from TV-SPEC-67180 v3.0 to TV-SPEC-67180 v4.0 at the INH+GLO+CHAR Limit Type
3. Update SMD from TV-SPEC-66430 v5.0 to TV-SPEC-66430 v6.0 at the INH+CLIN+CHAR 2 Limit Type
4. R Volume 1 (v1) 1N and R Volume 2 (v1) 1N added for clinical (CLIN) and PPQ (GLO)
5. CLIN+GLO (PPQ) acceptance criteria removed at IC 1X VOLUME 1/ Volume Average and IC 1X VOLUME 2 / Volume Average, parameter lists will be used only for commercial (GLO1)
6. Commercial (GLO1) acceptance criteria and unit updated at IC 1X VOLUME 1 / Volume Average and  IC 1X VOLUME 2 / Volume Average
7. Commercial (GLO1) acceptance criteria updated at CIEF (v1) 3N 1LIST 6 / Component 1+2
8. CoA Translation updated at PARTICULATE MATTER (v1) CNTO4424 1LIST and PARTICULATE MATTER 7 (v1) 1LIST
9. CoA Translation updated at IC A280 SAMPLE CONC / Protein Conc, Extended Info for GLO and CLIN removed since the CoA Translation is now aligned
10. Commercial (GLO1) acceptance criteria updated at PH20 ACTIVITY (v1) 1N
11. CoA Translation updated at PEPTIDE MAPPING 1 (v1) 5N / Component 1, Extended Info for CHAR and CHAR 2 removed since the CoA Translation is now aligned
12. BIOASSAY (v1) 0 PCT removed
13. CHAR (PPQ) and CHAR 2 (clininal) acceptance criteria at PEPTIDE MAPPING 1 (v1) 5N / Component 5 removed. (After the launch according to ETS 2387769 and the performed Spec assignment on the batches, parameter list will be replaced by a 4N variant.)
14. ALERT limit type updated as per TV-SPEC-69985 v2.0
15. GLO1+CLIN limit added at PARTICULATE MATTER 8
16. CLIN limit added at IC 1X VOLUME 3 + IC 1X VOLUME 4
17. Update CoA Translation at PARTICULATE MATTER 8 (v1) 1LIST and added extended Info for GLO+CLIN",,,tlinack,lwerner3,ETS 2387769 + 2375655 + ETS 2192559,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Tue Dec 10 06:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01939531-58fc-720e-b1c3-940b3601e609-123-Spec-00040113|28|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","01939531-58fc-720e-b1c3-940b3601e609","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|28|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"28",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"04/Dec/2024 - tlinack (SC) - Update of specification report.  - ETS 2387769 + 2375655 + ETS 2192559
1. Update SMD from TV-SPEC-69985 v1.0 to TV-SPEC-69985 v2.0 at INH+GLO 1+CHAR 1+ALERT Limit Type
2. Update SMD from TV-SPEC-67180 v3.0 to TV-SPEC-67180 v4.0 at the INH+GLO+CHAR Limit Type
3. Update SMD from TV-SPEC-66430 v5.0 to TV-SPEC-66430 v6.0 at the INH+CLIN+CHAR 2 Limit Type
4. R Volume 1 (v1) 1N and R Volume 2 (v1) 1N added for clinical (CLIN) and PPQ (GLO)
5. CLIN+GLO (PPQ) acceptance criteria removed at IC 1X VOLUME 1/ Volume Average and IC 1X VOLUME 2 / Volume Average, parameter lists will be used only for commercial (GLO1)
6. Commercial (GLO1) acceptance criteria and unit updated at IC 1X VOLUME 1 / Volume Average and  IC 1X VOLUME 2 / Volume Average
7. Commercial (GLO1) acceptance criteria updated at CIEF (v1) 3N 1LIST 6 / Component 1+2
8. CoA Translation updated at PARTICULATE MATTER (v1) CNTO4424 1LIST and PARTICULATE MATTER 7 (v1) 1LIST
9. CoA Translation updated at IC A280 SAMPLE CONC / Protein Conc, Extended Info for GLO and CLIN removed since the CoA Translation is now aligned
10. Commercial (GLO1) acceptance criteria updated at PH20 ACTIVITY (v1) 1N
11. CoA Translation updated at PEPTIDE MAPPING 1 (v1) 5N / Component 1, Extended Info for CHAR and CHAR 2 removed since the CoA Translation is now aligned
12. BIOASSAY (v1) 0 PCT removed
13. CHAR (PPQ) and CHAR 2 (clininal) acceptance criteria at PEPTIDE MAPPING 1 (v1) 5N / Component 5 removed. (After the launch according to ETS 2387769 and the performed Spec assignment on the batches, parameter list will be replaced by a 4N variant.)
14. ALERT limit type updated as per TV-SPEC-69985 v2.0
15. GLO1+CLIN limit added at PARTICULATE MATTER 8
16. CLIN limit added at IC 1X VOLUME 3 + IC 1X VOLUME 4
17. Update CoA Translation at PARTICULATE MATTER 8 (v1) 1LIST and added extended Info for GLO+CLIN",,,tlinack,lwerner3,ETS 2387769 + 2375655 + ETS 2192559,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Tue Dec 10 06:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01939531-5b9b-7945-800a-e0240f792833-123-Spec-00040113|28|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","01939531-5b9b-7945-800a-e0240f792833","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|28|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"28",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"04/Dec/2024 - tlinack (SC) - Update of specification report.  - ETS 2387769 + 2375655 + ETS 2192559
1. Update SMD from TV-SPEC-69985 v1.0 to TV-SPEC-69985 v2.0 at INH+GLO 1+CHAR 1+ALERT Limit Type
2. Update SMD from TV-SPEC-67180 v3.0 to TV-SPEC-67180 v4.0 at the INH+GLO+CHAR Limit Type
3. Update SMD from TV-SPEC-66430 v5.0 to TV-SPEC-66430 v6.0 at the INH+CLIN+CHAR 2 Limit Type
4. R Volume 1 (v1) 1N and R Volume 2 (v1) 1N added for clinical (CLIN) and PPQ (GLO)
5. CLIN+GLO (PPQ) acceptance criteria removed at IC 1X VOLUME 1/ Volume Average and IC 1X VOLUME 2 / Volume Average, parameter lists will be used only for commercial (GLO1)
6. Commercial (GLO1) acceptance criteria and unit updated at IC 1X VOLUME 1 / Volume Average and  IC 1X VOLUME 2 / Volume Average
7. Commercial (GLO1) acceptance criteria updated at CIEF (v1) 3N 1LIST 6 / Component 1+2
8. CoA Translation updated at PARTICULATE MATTER (v1) CNTO4424 1LIST and PARTICULATE MATTER 7 (v1) 1LIST
9. CoA Translation updated at IC A280 SAMPLE CONC / Protein Conc, Extended Info for GLO and CLIN removed since the CoA Translation is now aligned
10. Commercial (GLO1) acceptance criteria updated at PH20 ACTIVITY (v1) 1N
11. CoA Translation updated at PEPTIDE MAPPING 1 (v1) 5N / Component 1, Extended Info for CHAR and CHAR 2 removed since the CoA Translation is now aligned
12. BIOASSAY (v1) 0 PCT removed
13. CHAR (PPQ) and CHAR 2 (clininal) acceptance criteria at PEPTIDE MAPPING 1 (v1) 5N / Component 5 removed. (After the launch according to ETS 2387769 and the performed Spec assignment on the batches, parameter list will be replaced by a 4N variant.)
14. ALERT limit type updated as per TV-SPEC-69985 v2.0
15. GLO1+CLIN limit added at PARTICULATE MATTER 8
16. CLIN limit added at IC 1X VOLUME 3 + IC 1X VOLUME 4
17. Update CoA Translation at PARTICULATE MATTER 8 (v1) 1LIST and added extended Info for GLO+CLIN",,,tlinack,lwerner3,ETS 2387769 + 2375655 + ETS 2192559,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Tue Dec 10 06:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01939f82-51c4-764c-8b2d-d3c9b1108b16-123-Spec-00040098|21|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01939f82-51c4-764c-8b2d-d3c9b1108b16","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|21|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"21",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"06DEC2024 nchadwi2 (GQS) - updated specification per TruVault update / CC 2387769 and site LCRF ""2024-12-04_TV-eFRM-10818_v9.0 ABOV 28-NOV-24 - signed""
1. Updated SMD references for INH, GLO and CHAR limit types
2. Removed CHAR limit and CoA limit text for MULTI ATTR PEP MAP (v1) 5N component 5
3. Removed BIOASSAY (v1) 2N.
4. Added VISIBLE ADD INSPECT (v1) 1LIST 2N and configured CHAR limit type.
5. Added ALERT limit type with SMD reference TV-SPEC-69985 v2.0.
6. Configured ALERT limits for TURBIDITY 1 (v1) 1N, IC TURB AVG CV VERIF (v1) 7N 7NC, POLYSORBATE 80 (v1) 1N, CIEF (v1) 8N 1LIST, PARTICULATE MATTER 6 (v1) 8N, IC BIOASSAY SAC ST1 (v1) 1LIST 13N 1NC, IC BIOASSAY SAC ST2 (v1) 1LIST 11N 14NC, IC CMET BIND SAC (v1) 7N 1NC, PH20 ACTIVITY (v1) 1N, SE-HPLC (v1) 3N, CSDS REDUCED (v1) 2N 1LIST 3, CSDS NON-REDUCED (v1) 2N 1LIST 1, MULTI ATTR PEP MAP (v1) 5N and PEPTIDE MAPPING (v1) 15N.
7. Updated CoA translation, CoA limit text, dp and unit for IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT component Part./cont. 2-10um and added CHAR limit for same.",,,nchadwi2,WVeen1,CC2387769,"TV-SPEC-67180, TV-SPEC-69985",Tue Dec 10 06:00:00 EST 2024,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-0193b42b-8188-7e47-8876-90eb0f15e46f-123-Spec-00040113|29|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","0193b42b-8188-7e47-8876-90eb0f15e46f","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|29|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"29",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 13/Jan/2024 - ETS CC 2387769 - Update of specification report.
1. Updated SMD reference from TV-SPEC-69985 v2.0 to TV-SPEC-69985 v3.0 for Limit Type ALERT, GLO 1 and CHAR 1.
2. Updated SMD reference from TV-SPEC-69985 v2.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 for Limit Type INH.



10-Dec-2024 - lwerner3 (SC) - Update of specification report - ETS CC 2387769

New limit type ""US"" added with SMD Reference TV-SPEC-71673 v1.0
Added Param List ""POLYSORBATE 80 1"" for US limit type
Added Extended CoA Info for:
PARTICULATE MATTER (v1) CNTO4424 1LIST	Component 1 (Standard)
PARTICULATE MATTER 7 (v1) 1LIST	Component 1 (Standard)
IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=10um (Standard)	
IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=25um (Standard)	
IC SUBVIS 12 A (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=10um (Standard)	
IC SUBVIS 12 A (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=25um (Standard)	
PH20 ACTIVITY (v1) 1N	Component 1 (Standard)
CSDS REDUCED (v1) CNTO4424 2N 1LIST	Component 1 (Standard)
CSDS REDUCED (v1) CNTO4424 2N 1LIST	Component 3 (Standard)
CSDS NON-REDUCED (v1) 1N 1LIST 2	Component 1 (Standard)
CSDS NON-REDUCED (v1) 1N 1LIST 2	Component 2 (Standard)
PEPTIDE MAPPING 1 (v1) 5N	Component 1 (Standard)

08-Jan-2025 - lwerner3 (SC) - Update of specification report
1. Spec-00040113‎ is needed for an other update, therefore all changes have been reverted, due to a delay in the approval of TV-SPEC-71673 v1.0.",,,lwerner3,tshah1,Reviewed/Approved.,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri Jan 17 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0193b42b-8396-74af-a45d-fbd00a592c5b-123-Spec-00040113|29|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0193b42b-8396-74af-a45d-fbd00a592c5b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|29|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"29",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 13/Jan/2024 - ETS CC 2387769 - Update of specification report.
1. Updated SMD reference from TV-SPEC-69985 v2.0 to TV-SPEC-69985 v3.0 for Limit Type ALERT, GLO 1 and CHAR 1.
2. Updated SMD reference from TV-SPEC-69985 v2.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 for Limit Type INH.



10-Dec-2024 - lwerner3 (SC) - Update of specification report - ETS CC 2387769

New limit type ""US"" added with SMD Reference TV-SPEC-71673 v1.0
Added Param List ""POLYSORBATE 80 1"" for US limit type
Added Extended CoA Info for:
PARTICULATE MATTER (v1) CNTO4424 1LIST	Component 1 (Standard)
PARTICULATE MATTER 7 (v1) 1LIST	Component 1 (Standard)
IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=10um (Standard)	
IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=25um (Standard)	
IC SUBVIS 12 A (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=10um (Standard)	
IC SUBVIS 12 A (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=25um (Standard)	
PH20 ACTIVITY (v1) 1N	Component 1 (Standard)
CSDS REDUCED (v1) CNTO4424 2N 1LIST	Component 1 (Standard)
CSDS REDUCED (v1) CNTO4424 2N 1LIST	Component 3 (Standard)
CSDS NON-REDUCED (v1) 1N 1LIST 2	Component 1 (Standard)
CSDS NON-REDUCED (v1) 1N 1LIST 2	Component 2 (Standard)
PEPTIDE MAPPING 1 (v1) 5N	Component 1 (Standard)

08-Jan-2025 - lwerner3 (SC) - Update of specification report
1. Spec-00040113‎ is needed for an other update, therefore all changes have been reverted, due to a delay in the approval of TV-SPEC-71673 v1.0.",,,lwerner3,tshah1,Reviewed/Approved.,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri Jan 17 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0193b42b-8478-7242-8cac-86a6a499bd96-123-Spec-00040113|29|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","0193b42b-8478-7242-8cac-86a6a499bd96","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|29|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"29",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 13/Jan/2024 - ETS CC 2387769 - Update of specification report.
1. Updated SMD reference from TV-SPEC-69985 v2.0 to TV-SPEC-69985 v3.0 for Limit Type ALERT, GLO 1 and CHAR 1.
2. Updated SMD reference from TV-SPEC-69985 v2.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 for Limit Type INH.



10-Dec-2024 - lwerner3 (SC) - Update of specification report - ETS CC 2387769

New limit type ""US"" added with SMD Reference TV-SPEC-71673 v1.0
Added Param List ""POLYSORBATE 80 1"" for US limit type
Added Extended CoA Info for:
PARTICULATE MATTER (v1) CNTO4424 1LIST	Component 1 (Standard)
PARTICULATE MATTER 7 (v1) 1LIST	Component 1 (Standard)
IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=10um (Standard)	
IC SUBVIS 12 (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=25um (Standard)	
IC SUBVIS 12 A (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=10um (Standard)	
IC SUBVIS 12 A (v1) 4N 8NC 5DATE 1TEXT	Part./cont. >=25um (Standard)	
PH20 ACTIVITY (v1) 1N	Component 1 (Standard)
CSDS REDUCED (v1) CNTO4424 2N 1LIST	Component 1 (Standard)
CSDS REDUCED (v1) CNTO4424 2N 1LIST	Component 3 (Standard)
CSDS NON-REDUCED (v1) 1N 1LIST 2	Component 1 (Standard)
CSDS NON-REDUCED (v1) 1N 1LIST 2	Component 2 (Standard)
PEPTIDE MAPPING 1 (v1) 5N	Component 1 (Standard)

08-Jan-2025 - lwerner3 (SC) - Update of specification report
1. Spec-00040113‎ is needed for an other update, therefore all changes have been reverted, due to a delay in the approval of TV-SPEC-71673 v1.0.",,,lwerner3,tshah1,Reviewed/Approved.,"TV-SPEC-67180, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Fri Jan 17 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019453a7-6b24-7521-b29d-f4077253d030-123-Spec-00040098|22|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019453a7-6b24-7521-b29d-f4077253d030","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|22|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"22",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"BRaja5 (GVW) - 10/Jan/2025 - CC 2387769 - Update of Specification as per TruVault Document.
1. Updated SMD Reference from TV-SPEC-69985 v2.0 to TV-SPEC-69985 v3.0 for ALERT Limit Type.",,,BRaja5,tshah1,Reviewed/Approved.,"TV-SPEC-67180, TV-SPEC-69985",Fri Jan 17 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019453a7-7673-749d-b3c8-3eb75c689c43-123-Spec-00043112|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019453a7-7673-749d-b3c8-3eb75c689c43","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|10|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"10","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","BRaja5 (GVW) - 10/Jan/2025 - CC 2387769 - Update of Specification as per TruVault Document.
1. Updated SMD Reference from TV-SPEC-69985 v2.0 to TV-SPEC-69985 v3.0 for INH, GLO, PHASE 3, ALERT, and CHAR Limit Types.
",,,BRaja5,tshah1,Reviewed/Approved.,TV-SPEC-69985,Fri Jan 17 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019458ee-e423-795b-a084-bd20bdbf59f0-123-Spec-00043114|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019458ee-e423-795b-a084-bd20bdbf59f0","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|6|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"6",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,A,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"dpriyada (GVW) - 11/Jan/2025 - Update of specification as per TruVault Document.
1. Updated SMD Reference from TV-SPEC-69986 v2.0 to TV-SPEC-69986 v3.0 for all Limit Types.",,,dpriyada,tshah1,Reviewed/Approved.,TV-SPEC-69986,Fri Jan 17 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-019477bb-1548-7575-9ab3-c4e231501599-123-Spec-00043112|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019477bb-1548-7575-9ab3-c4e231501599","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|11|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"11","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","PKuruva (GVW) - 17/Jan/2025 - CAPA 2375314 - Update of specification as per LCRF.
1. Updated Threshold values for applicable components of MULTI ATTR PEP MAP parameter list.
",,,pkuruva,Mcolli34,Reviewed/Approved as per LCRF,TV-SPEC-69985,Tue Feb 04 14:37:21 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019477bb-169b-7485-8a9c-2e5ae7295768-123-Spec-00040098|23|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019477bb-169b-7485-8a9c-2e5ae7295768","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|23|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"23",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"PKuruva (GVW) - 17/Jan/2025 - CAPA 2375314 - Update of specification as per LCRF.
1. Updated Threshold values for ""Component 7"" and ""Component 8"" of CIEF parameter list.",,,pkuruva,Mcolli34,Reviewed/Approved as per LCRF,"TV-SPEC-69985, TV-SPEC-67180",Thu Jan 30 19:57:23 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-019477bb-1803-7b10-a4cb-8e373fcc0d2e-123-Spec-00043114|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","019477bb-1803-7b10-a4cb-8e373fcc0d2e","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|7|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"7",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,C,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"RDhanas2 (GVW) - 17/Jan/2025 - Update of specification as per LCRF.
1. Added PHASE 3 Limits for applicable parameters of COLOR OF SOLUTION 1, IC PH MEASUREMENT, CIEF 1, DOT BLOT IDENTITY 1, IC A280 SAMPLE, IC BIOASSAY SAC ST1, BINDING ASSAY 1, IC CMET BIND SAC, SE-HPLC 1, CSDS REDUCED 1, CSDS NON-REDUCED 1 and HI HPLC 1 parameter lists.
2. Added Extended CoA Limit Text for applicable parameters of IC BIOASSAY SAC ST1, BINDING ASSAY 1 and IC CMET BIND SAC parameter lists.
3. Removed CoA Limit Text and added Extended CoA Limit Text for ""Component 3"" of SE-HPLC 1 parameter list.
4. Removed BINDING ASSAY parameter list.
5. Updated Technique for BIOASSAY parameter list.
6. Updated CoA Translation for “Component 3"" of SE-HPLC 1 parameter list.
7. Updated Threshold values for “Component 2” and “Component 3” of SE-HPLC 1 parameter list.
8. Updated CoA Group for ""Component 3"" of SE-HPLC 1 parameter list.
9. Added CoA Limit Text for “Component 8"" of CIEF 1 parameter list.
10. Updated CoA Limit Text for ""Component 1"" of COLOR OF SOLUTION 1 parameter list.",,,rdhanas2,Lwiertzb,Review and approval GQS per LCRF request,TV-SPEC-69986,Fri Jan 17 14:25:11 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0194bfa2-38a4-7aeb-a87e-44b063eca61d-123-Spec-00040113|30|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","0194bfa2-38a4-7aeb-a87e-44b063eca61d","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|30|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"30",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 20/Jan/2024 - Update of specification report as per LCRF.
1. Updated SMD Reference from TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 for Limit Type INH.
2. Updated SMD Reference from TV-VAL-278811 v1.0 to TV-TEC-309014 v1.0 for Limit Type IPC.
3. Updated Inhouse Reference from ""PPQ and Post PPQ"" to ""Post PPQ"" for Limit Types GLO, CHAR and IPC.
4. Replaced parameter list ""PEPTIDE MAPPING 1 (v1) 5N"" with ""PEPTIDE MAPPING 1 (v1) 4N"".

",,,Gchokkal,lwerner3,LCRF,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jan 22 15:05:57 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0194bfa2-3dea-7382-8a55-4fe3b2bcd8a6-123-Spec-00040098|24|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0194bfa2-3dea-7382-8a55-4fe3b2bcd8a6","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|24|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"24",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"BRaja5 (GVW) - 31/Jan/2025 - Update of Specification as per LCRF.
1. Removed CIEF parameter list.
2. Added CIEF 2 parameter list.
",,,BRaja5,tshah1,Reviewed/Approved.,"TV-SPEC-69985, TV-SPEC-67180",Fri Jan 31 12:34:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-0194bfa2-3e48-7cf4-86fb-f35e3f6bbf79-123-Spec-00040113|30|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0194bfa2-3e48-7cf4-86fb-f35e3f6bbf79","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|30|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"30",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 20/Jan/2024 - Update of specification report as per LCRF.
1. Updated SMD Reference from TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 for Limit Type INH.
2. Updated SMD Reference from TV-VAL-278811 v1.0 to TV-TEC-309014 v1.0 for Limit Type IPC.
3. Updated Inhouse Reference from ""PPQ and Post PPQ"" to ""Post PPQ"" for Limit Types GLO, CHAR and IPC.
4. Replaced parameter list ""PEPTIDE MAPPING 1 (v1) 5N"" with ""PEPTIDE MAPPING 1 (v1) 4N"".

",,,Gchokkal,lwerner3,LCRF,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jan 22 15:05:57 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0194bfa2-444f-756c-b37f-096d95aa5be8-123-Spec-00040113|30|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","0194bfa2-444f-756c-b37f-096d95aa5be8","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|30|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"30",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"Gchokkal (GVW) - 20/Jan/2024 - Update of specification report as per LCRF.
1. Updated SMD Reference from TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-VAL-278811 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 for Limit Type INH.
2. Updated SMD Reference from TV-VAL-278811 v1.0 to TV-TEC-309014 v1.0 for Limit Type IPC.
3. Updated Inhouse Reference from ""PPQ and Post PPQ"" to ""Post PPQ"" for Limit Types GLO, CHAR and IPC.
4. Replaced parameter list ""PEPTIDE MAPPING 1 (v1) 5N"" with ""PEPTIDE MAPPING 1 (v1) 4N"".

",,,Gchokkal,lwerner3,LCRF,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-54413, TV-SPEC-61505",Wed Jan 22 15:05:57 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0194cf30-89e0-72eb-87fe-b210850257f7-123-Spec-00040098|25|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0194cf30-89e0-72eb-87fe-b210850257f7","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|25|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"25",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,A,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"BRaja5 (GVW) - 05/Feb/2025 - CAPA-001651 - Update of Specification as per LCRF.
1. Removed GLO Limits and CoA Limit Text for parameter ‘result EP-B’, ‘result EP-BY’ and ‘result EP-Y’ of IC COLOR INST SAMPLE parameter list.
2. Added GLO Limits and CoA Limit Text for parameter ‘result EP-B rep’, ‘result EP-BY rep’ and ‘result EP-Y rep’ of IC COLOR INST SAMPLE parameter list.
3. Updated CoA Translation for all applicable parameters of IC COLOR INST SAMPLE parameter list.",,,BRaja5,SKuijla2,GQS Reviewed/Approved,"TV-SPEC-67180, TV-SPEC-69985",Wed Feb 12 10:57:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-0194d9c1-6459-7563-b3da-f0a8e4d0c7c5-123-Spec-00043112|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0194d9c1-6459-7563-b3da-f0a8e4d0c7c5","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|12|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"12","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",A,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","BRaja5 (GVW) - 05/Feb/2025 - CAPA-001651 - Update of Specification as per LCRF.
1. Removed PHASE 3 Limits and CoA Limit Text for parameter ""result EP-B"", ""result EP-BY"" and ""result EP-Y"" of IC COLOR INST SAMPLE parameter list.
2. Added PHASE 3 Limits and CoA Limit Text for parameter ""result EP-B rep"", ""result EP-BY rep"" and ""result EP-Y rep"" of IC COLOR INST SAMPLE parameter list.
3. Updated CoA Translation for all applicable parameters of IC COLOR INST SAMPLE parameter list.
",,,BRaja5,Mcolli34,Reviewed/Approved as per LCRF,TV-SPEC-69985,Wed Feb 12 10:59:16 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-01952c8e-6047-7943-aedb-916d0517d8e8-123-Spec-00040113|31|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","01952c8e-6047-7943-aedb-916d0517d8e8","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|31|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"31",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"lwerner3 (SC) - update of specification report according to TV-SPEC-70238 v2.0 / ETS#CC2387287

1. update of SMD reference on limit type IPC 1 from TV-SPEC-70238 v1.0 to TV-SPEC-70238 v2.0
2. update of SMD reference on limit type INH from TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0",,,lwerner3,tlinack,ETS 2387287,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-54413, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-61505, TV-SPEC-66430, TV-SPEC-69985",Fri Feb 28 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01952c8e-645d-7df5-a4c8-2e66f939c2d2-123-Spec-00040113|31|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","01952c8e-645d-7df5-a4c8-2e66f939c2d2","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|31|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"31",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"lwerner3 (SC) - update of specification report according to TV-SPEC-70238 v2.0 / ETS#CC2387287

1. update of SMD reference on limit type IPC 1 from TV-SPEC-70238 v1.0 to TV-SPEC-70238 v2.0
2. update of SMD reference on limit type INH from TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0",,,lwerner3,tlinack,ETS 2387287,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-54413, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-61505, TV-SPEC-66430, TV-SPEC-69985",Fri Feb 28 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01952c8e-6761-7778-b195-300826898f9b-123-Spec-00040113|31|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01952c8e-6761-7778-b195-300826898f9b","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|31|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"31",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"lwerner3 (SC) - update of specification report according to TV-SPEC-70238 v2.0 / ETS#CC2387287

1. update of SMD reference on limit type IPC 1 from TV-SPEC-70238 v1.0 to TV-SPEC-70238 v2.0
2. update of SMD reference on limit type INH from TV-SPEC-69985 v3.0, TV-SPEC-70238 v1.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v3.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0",,,lwerner3,tlinack,ETS 2387287,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-54413, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-61505, TV-SPEC-66430, TV-SPEC-69985",Fri Feb 28 06:00:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-01952c8e-6fe9-70a4-89f6-c13e16ed9f12-123-Spec-00043112|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01952c8e-6fe9-70a4-89f6-c13e16ed9f12","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043112|13|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043112,"13","AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB",C,"AMIVANTAMAB SC DRUG PRODUCT (1600, 2240 MG) LABORATORY SPECIFICATIONS - STAB","pkalaimo (GVW) - 12/Feb/2025 - CAPA-001651 - Update of Specification as per site request.
1. Updated PHASE 3 Limits for parameter ""result EP-B rep"", ""result EP-BY rep"" and ""result EP-Y rep"" of IC COLOR INST SAMPLE parameter list.
2. Updated CoA Translation for applicable parameters of IC COLOR INST SAMPLE parameter list.",,,pkalaimo,tshah1,Reviewed/Approved.,TV-SPEC-69985,Thu Feb 13 15:50:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-01952c8e-7063-7f3b-ba06-17ade02a9796-123-Spec-00040098|26|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","01952c8e-7063-7f3b-ba06-17ade02a9796","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040098|26|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040098,"26",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - STAB,"dpriyada (GVW) - 12/Feb/2025 - CAPA-001651 - Update of Specification as per site request. 
1. Updated GLO Limits for parameter ""result EP-B rep"", ""result EP-BY rep"" and ""result EP-Y rep"" of IC COLOR INST SAMPLE parameter list. 
2. Updated CoA Translation for applicable parameters of IC COLOR INST SAMPLE parameter list.",,,dpriyada,tshah1,Reviewed/Approved.,"TV-SPEC-67180, TV-SPEC-69985",Thu Feb 13 15:47:00 EST 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,T
"01968265-dd3a-7ecf-97ba-98a42721ed68-0196a37e-952f-7c34-8e8e-0c8b01fcbb46-123-Spec-00040113|34|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0196a37e-952f-7c34-8e8e-0c8b01fcbb46","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|34|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00040113,"34",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"09-April-2025 tlinack (SC) - Update as per LCRF
1. Update SMD Reference from TV-TEC-309014 v1.0 to TV-TEC-309014 v2.0 at the IPC Limit Type
2. Update SMD Reference from TV-TEC-250649 v5.0 to TV-TEC-309014 v2.0 at the IPC 2 Limit Type
3. Update SMD Reference from TV-SPEC-69985 v4.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v4.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v2.0, TV-SPEC-66430 v6.0
",,,tlinack,nsatzing,CHG-019931 & TV-TEC-309014 v2.0,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-72482, TV-SPEC-54413, TV-SPEC-61505",Thu Apr 10 06:00:00 EDT 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0196a37e-b942-74be-86ee-012f9b3b9336-123-Spec-00040113|34|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%","0196a37e-b942-74be-86ee-012f9b3b9336","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|34|15N|PEPTIDE MAPPING : Component 15|CHAR 2|Not In|-99999|||%,Spec-00040113,"34",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"09-April-2025 tlinack (SC) - Update as per LCRF
1. Update SMD Reference from TV-TEC-309014 v1.0 to TV-TEC-309014 v2.0 at the IPC Limit Type
2. Update SMD Reference from TV-TEC-250649 v5.0 to TV-TEC-309014 v2.0 at the IPC 2 Limit Type
3. Update SMD Reference from TV-SPEC-69985 v4.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v4.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v2.0, TV-SPEC-66430 v6.0
",,,tlinack,nsatzing,CHG-019931 & TV-TEC-309014 v2.0,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-72482, TV-SPEC-54413, TV-SPEC-61505",Thu Apr 10 06:00:00 EDT 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 2,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0196a37e-da82-7e39-8aa5-eec7141fc2d1-123-Spec-00040113|34|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%","0196a37e-da82-7e39-8aa5-eec7141fc2d1","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00040113|34|15N|PEPTIDE MAPPING : Component 15|CHAR 1|Not In|-99999|||%,Spec-00040113,"34",JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT,C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB SUBCUTANEOUS GEN2 PPQ AND POST-PPQ DRUG PRODUCT - RELEASE - (SC),"09-April-2025 tlinack (SC) - Update as per LCRF
1. Update SMD Reference from TV-TEC-309014 v1.0 to TV-TEC-309014 v2.0 at the IPC Limit Type
2. Update SMD Reference from TV-TEC-250649 v5.0 to TV-TEC-309014 v2.0 at the IPC 2 Limit Type
3. Update SMD Reference from TV-SPEC-69985 v4.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v1.0, TV-SPEC-66430 v6.0, TV-TEC-250649 v5.0 to TV-SPEC-69985 v4.0, TV-SPEC-70238 v2.0, TV-SPEC-67180 v4.0, TV-TEC-309014 v2.0, TV-SPEC-66430 v6.0
",,,tlinack,nsatzing,CHG-019931 & TV-TEC-309014 v2.0,"TV-SPEC-67180, TV-TEC-309014, TV-SPEC-70238, TV-TEC-250649, TV-SPEC-66430, TV-SPEC-69985, TV-SPEC-72482, TV-SPEC-54413, TV-SPEC-61505",Thu Apr 10 06:00:00 EDT 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR 1,Not In -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0196b07a-3547-739a-b731-772aa0768b99-123-Spec-00043114|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0196b07a-3547-739a-b731-772aa0768b99","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|15|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"15",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,C,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"RDhanas2 (GVW) - 29/Apr/2025 - Update of specification as per LCRF.
1. Updated Work sheet Template for IC CMET BIND SAC and IC BIOASSAY SAC ST1 parameter list.
2. Added CoA Limit Text for parameter ""AAC Evaluation"" IC CMET BIND SAC and parameter ""AAC Crosslink ST1"" IC BIOASSAY SAC ST1 parameter list.
3. Updated Technique for BIOASSAY and IC BIOASSAY SAC ST1 parameter list.
4. Added IC BIOASSAY SAC ST2 parameter list.",,,rdhanas2,tshah1,Reviewed/Approved.,TV-SPEC-69986,Tue May 06 12:45:00 EDT 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0196b07a-3588-70c0-b37e-ecc72c280712-123-Spec-00043114|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0196b07a-3588-70c0-b37e-ecc72c280712","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00043114|14|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00043114,"14",AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,A,AMIVANTAMAB 160 MG/ML DRUG SUBSTANCE LABORATORY SPECIFICATIONS,"cgili (Global eLIMS) 10APR2025: As per LCRF (TV-SPEC-69986 V3.0)
1. Updated Units for Param List SE-HPLC 1 (3N) to % 
2. Updated  Display format for Param List SE-HPLC 1 (3N) to 0.0",,,cgili,tshah1,Reviewed/Approved.,TV-SPEC-69986,Thu Apr 10 20:58:00 EDT 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
"01968265-dd3a-7ecf-97ba-98a42721ed68-0196b07a-499b-746a-9c1b-94686d396816-123-Spec-00039784|17|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%","0196b07a-499b-746a-9c1b-94686d396816","01968265-dd3a-7ecf-97ba-98a42721ed68",CypressTC3 – Streamer Test,"123",2025-05-12 00:00:00.000,Spec-00039784|17|15N|PEPTIDE MAPPING : Component 15|CHAR|>|-99999|||%,Spec-00039784,"17",JNJ-61186372 160 MG/ML GEN2 SBL/CORK PPQ FORMULATED BULK (MM#310817; A3E/563475),C,SPECIFICATIONS AND JUSTIFICATION OF SPECIFICATIONS FOR JNJ-61186372 AMIVANTAMAB 160 MG/ML GEN2 SBL/CORK AND SBL-P4 PPQ AND POST-PPQ FORMULATED BULK   (GLOBAL MM#310817; A3E/563475),"RDhanas2 (GVW) - 29/Apr/2025 - Update of specification as per LCRF.
1. Updated Work sheet Template for IC CMET BIND SAC and IC BIOASSAY SAC ST1 parameter list.
2. Updated Method Reference for and IC BIOASSAY SAC ST1 parameter list.
3. Added CoA Limit Text for parameter ""AAC Evaluation"" IC CMET BIND SAC and parameter ""AAC Crosslink ST1"" IC BIOASSAY SAC ST1 parameter list.
4. Added IC BIOASSAY SAC ST2 parameter list.
5. Updated Technique for IC BIOASSAY SAC ST1 parameter list.
6. Updated INH Limit for parameter "" Lower CI"" and ""Upper CI"" of IC BIOASSAY SAC ST1 parameter list.
",,,rdhanas2,tshah1,Reviewed/Approved.,TV-SPEC-67179,Tue May 06 12:45:00 EDT 2025,PEPTIDE MAPPING,Component 15,PEPTIDE MAPPING : Component 15,CHAR,> -99999,,%,F
